<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:03:48Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5300259" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5300259</identifier><datestamp>2017-02-28</datestamp><setSpec>plosone</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, CA USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5300259</article-id>
      <article-id pub-id-type="pmcid">PMC5300259</article-id>
      <article-id pub-id-type="pmc-uid">5300259</article-id>
      <article-id pub-id-type="pmid">28182669</article-id>
      <article-id pub-id-type="pmid">28182669</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0170818</article-id>
      <article-id pub-id-type="publisher-id">PONE-D-16-37412</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Biochemistry</subject>
            <subj-group>
              <subject>Neurochemistry</subject>
              <subj-group>
                <subject>Neurotransmitters</subject>
                <subj-group>
                  <subject>Glutamate</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Neuroscience</subject>
            <subj-group>
              <subject>Neurochemistry</subject>
              <subj-group>
                <subject>Neurotransmitters</subject>
                <subj-group>
                  <subject>Glutamate</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Neurology</subject>
            <subj-group>
              <subject>Epilepsy</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Physical Sciences</subject>
          <subj-group>
            <subject>Chemistry</subject>
            <subj-group>
              <subject>Chemical Compounds</subject>
              <subj-group>
                <subject>Organic Compounds</subject>
                <subj-group>
                  <subject>Amino Acids</subject>
                  <subj-group>
                    <subject>Aliphatic Amino Acids</subject>
                    <subj-group>
                      <subject>Glycine</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Physical Sciences</subject>
          <subj-group>
            <subject>Chemistry</subject>
            <subj-group>
              <subject>Organic Chemistry</subject>
              <subj-group>
                <subject>Organic Compounds</subject>
                <subj-group>
                  <subject>Amino Acids</subject>
                  <subj-group>
                    <subject>Aliphatic Amino Acids</subject>
                    <subj-group>
                      <subject>Glycine</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Biochemistry</subject>
            <subj-group>
              <subject>Proteins</subject>
              <subj-group>
                <subject>Amino Acids</subject>
                <subj-group>
                  <subject>Aliphatic Amino Acids</subject>
                  <subj-group>
                    <subject>Glycine</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Physical Sciences</subject>
          <subj-group>
            <subject>Physics</subject>
            <subj-group>
              <subject>Nuclear Physics</subject>
              <subj-group>
                <subject>Nucleons</subject>
                <subj-group>
                  <subject>Protons</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Research and Analysis Methods</subject>
          <subj-group>
            <subject>Experimental Organism Systems</subject>
            <subj-group>
              <subject>Model Organisms</subject>
              <subj-group>
                <subject>Xenopus</subject>
                <subj-group>
                  <subject>Xenopus Oocytes</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Research and Analysis Methods</subject>
          <subj-group>
            <subject>Model Organisms</subject>
            <subj-group>
              <subject>Xenopus</subject>
              <subj-group>
                <subject>Xenopus Oocytes</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Research and Analysis Methods</subject>
          <subj-group>
            <subject>Experimental Organism Systems</subject>
            <subj-group>
              <subject>Animal Models</subject>
              <subj-group>
                <subject>Xenopus</subject>
                <subj-group>
                  <subject>Xenopus Oocytes</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Organisms</subject>
            <subj-group>
              <subject>Animals</subject>
              <subj-group>
                <subject>Vertebrates</subject>
                <subj-group>
                  <subject>Amphibians</subject>
                  <subj-group>
                    <subject>Frogs</subject>
                    <subj-group>
                      <subject>Xenopus</subject>
                      <subj-group>
                        <subject>Xenopus Oocytes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Physiology</subject>
            <subj-group>
              <subject>Physiological Processes</subject>
              <subj-group>
                <subject>Sleep</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Physiology</subject>
            <subj-group>
              <subject>Physiological Processes</subject>
              <subj-group>
                <subject>Sleep</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Genetics</subject>
            <subj-group>
              <subject>Mutation</subject>
              <subj-group>
                <subject>Missense Mutation</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Neuroscience</subject>
            <subj-group>
              <subject>Sensory Perception</subject>
              <subj-group>
                <subject>Sensory Receptors</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Psychology</subject>
            <subj-group>
              <subject>Sensory Perception</subject>
              <subj-group>
                <subject>Sensory Receptors</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Social Sciences</subject>
          <subj-group>
            <subject>Psychology</subject>
            <subj-group>
              <subject>Sensory Perception</subject>
              <subj-group>
                <subject>Sensory Receptors</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Cell Biology</subject>
            <subj-group>
              <subject>Signal Transduction</subject>
              <subj-group>
                <subject>Sensory Receptors</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A <italic>de novo</italic> loss-of-function <italic>GRIN2A</italic> mutation associated with childhood focal epilepsy and acquired epileptic aphasia</article-title>
        <alt-title alt-title-type="running-head"><italic>GRIN2A</italic> mutation in focal epilepsy</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Gao</surname>
            <given-names>Kai</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Tankovic</surname>
            <given-names>Anel</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Yujia</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kusumoto</surname>
            <given-names>Hirofumi</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Jin</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
          <xref ref-type="author-notes" rid="currentaff001">
            <sup>Â¤</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Wenjuan</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff003">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>XiangWei</surname>
            <given-names>Wenshu</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shaulsky</surname>
            <given-names>Gil H.</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>Chun</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Traynelis</surname>
            <given-names>Stephen F.</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff004">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yuan</surname>
            <given-names>Hongjie</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff004">
            <sup>4</sup>
          </xref>
          <xref ref-type="corresp" rid="cor001">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>Yuwu</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff005">
            <sup>5</sup>
          </xref>
          <xref ref-type="corresp" rid="cor001">*</xref>
        </contrib>
      </contrib-group>
      <aff id="aff001"><label>1</label>
<addr-line>Department of Pediatrics and Pediatric Epilepsy Center, Peking University First Hospital, Beijing, China</addr-line></aff>
      <aff id="aff002"><label>2</label>
<addr-line>Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, United States of America</addr-line></aff>
      <aff id="aff003"><label>3</label>
<addr-line>Department of Neurology, Xiangya Hospital, Central South University, Changsha, China</addr-line></aff>
      <aff id="aff004"><label>4</label>
<addr-line>Center for Functional Evaluation of Rare Variant (CFERV), Emory University School of Medicine, Atlanta, GA, United States of America</addr-line></aff>
      <aff id="aff005"><label>5</label>
<addr-line>Center of Epilepsy, Beijing Institute for Brain Disorders, Beijing, China</addr-line></aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Mothet</surname>
            <given-names>Jean-Pierre</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>Aix-Marseille Universite, FRANCE</addr-line>
      </aff>
      <author-notes>
        <fn fn-type="COI-statement" id="coi001">
          <p><bold>Competing Interests: </bold>S.F.T. is a paid consultant for Janssen Pharmaceuticals, NeurOp, Inc., and Pfizer Inc, and co-founder of NeurOp Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
        </fn>
        <fn fn-type="con">
          <p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> SFT HY YJ.</p></list-item><list-item><p><bold>Data curation:</bold> SFT HY YJ.</p></list-item><list-item><p><bold>Formal analysis:</bold> KG SFT HY YJ.</p></list-item><list-item><p><bold>Funding acquisition:</bold> SFT HY YJ.</p></list-item><list-item><p><bold>Investigation:</bold> KG AT YZ HK JZ WC WX GHS CH HY.</p></list-item><list-item><p><bold>Methodology:</bold> SFT HY YJ.</p></list-item><list-item><p><bold>Project administration:</bold> SFT HY YJ.</p></list-item><list-item><p><bold>Resources:</bold> SFT HY YJ.</p></list-item><list-item><p><bold>Supervision:</bold> SFT HY YJ.</p></list-item><list-item><p><bold>Validation:</bold> KG SFT HY YJ.</p></list-item><list-item><p><bold>Visualization:</bold> KG HY.</p></list-item><list-item><p><bold>Writing â original draft:</bold> KG AT YZ WC WX CH SFT HY YJ.</p></list-item><list-item><p><bold>Writing â review &amp; editing:</bold> KG HK JZ GHS SFT HY YJ.</p></list-item></list>
</p>
        </fn>
        <fn fn-type="current-aff" id="currentaff001">
          <label>Â¤</label>
          <p>Current Address: Department of Neurology, Shanxi Medical University First Hospital, Taiyuan, China</p>
        </fn>
        <corresp id="cor001">* E-mail: <email>hyuan@emory.edu</email> (HY); <email>jiangyuwu@bjmu.edu.cn</email> (YJ)</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2017</year>
      </pub-date>
      <volume>12</volume>
      <issue>2</issue>
      <elocation-id>e0170818</elocation-id>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>10</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>1</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2017 Gao et al</copyright-statement>
        <copyright-year>2017</copyright-year>
        <copyright-holder>Gao et al</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="pone.0170818.pdf"/>
      <abstract>
        <sec id="sec001">
          <title>Objective</title>
          <p>N-methyl-D-aspartate receptors (NMDAR) subunit <italic>GRIN2A</italic>/GluN2A mutations have been identified in patients with various neurological diseases, such as epilepsy and intellectual disability / developmental delay (ID/DD). In this study, we investigated the phenotype and underlying molecular mechanism of a <italic>GRIN2A</italic> missense mutation identified by next generation sequencing on idiopathic focal epilepsy using <italic>in vitro</italic> electrophysiology.</p>
        </sec>
        <sec id="sec002">
          <title>Methods</title>
          <p>Genomic DNA of patients with epilepsy and ID/DD were sequenced by targeted next-generation sequencing within 300 genes related to epilepsy and ID/DD. The effects of one missense <italic>GRIN2A</italic> mutation on NMDAR function were evaluated by two-electrode voltage clamp current recordings and whole cell voltage clamp current recordings.</p>
        </sec>
        <sec id="sec003">
          <title>Results</title>
          <p>We identified one <italic>de novo</italic> missense <italic>GRIN2A</italic> mutation (Asp731Asn, GluN2A(D731N)) in a child with unexplained epilepsy and DD. The D731N mutation is located in a portion of the agonist-binding domain (ABD) in the GluN2A subunit, which is the binding pocket for agonist glutamate. This residue in the ABD is conserved among vertebrate species and all other NMDAR subunits, suggesting an important role in receptor function. The proband shows developmental delay as well as EEG-confirmed seizure activity. Functional analyses reveal that the GluN2A(D731N) mutation decreases glutamate potency by over 3,000-fold, reduces amplitude of current response, shortens synaptic-like response time course, and decreases channel open probability, while enhancing sensitivity to negative allosteric modulators, including extracellular proton and zinc inhibition. The combined effects reduce NMDAR function.</p>
        </sec>
        <sec id="sec004">
          <title>Significance</title>
          <p>We identified a <italic>de novo</italic> missense mutation in the <italic>GRIN2A</italic> gene in a patient with childhood focal epilepsy and acquired epileptic aphasia. The mutant decreases NMDAR activation suggesting NMDAR hypofunction may contribute to the epilepsy pathogenesis.</p>
        </sec>
      </abstract>
      <funding-group>
        <funding-statement>This work was supported by the Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development (NICHD) of the National Institutes of Health (NIH) under award number R01HD082373 to H.Y., by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) under award number R01NS036654, R01NS065371, R24NS092989 to S.F.T., by the Xiangya-Emory Medical Schools Visiting Student Program to W.C.; by the National Basic Research Program of China (973 program, grant number: 2012CB944600), by the National Natural Science Foundation of China (grant number: 81271439), by the Beijing Natural Science Foundation (grant number: 7151010), by the Beijing Municipal Science &amp; Technology Commission (grant number: Z161100000216133), by the Beijing Institute for Brain Disorders Foundation (grant number: BIBDPXM2014_014226_000016) and the Beijing Municipal Natural Science Key Project (grant number: 15G10050). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="6"/>
        <table-count count="4"/>
        <page-count count="20"/>
      </counts>
      <custom-meta-group>
        <custom-meta id="data-availability">
          <meta-name>Data Availability</meta-name>
          <meta-value>All relevant data are within the paper.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <title>Data Availability</title>
      <p>All relevant data are within the paper.</p>
    </notes>
  </front>
  <body>
    <sec sec-type="intro" id="sec005">
      <title>Introduction</title>
      <p>N-methyl-D-aspartate receptors (NMDARs), ligand-gated cation channels, mediate the slow component of excitatory synaptic transmission [<xref rid="pone.0170818.ref001" ref-type="bibr">1</xref>]. NMDARs are heterotetramers composed of two glycine-binding GluN1 subunits and two glutamate-binding GluN2 subunits [<xref rid="pone.0170818.ref001" ref-type="bibr">1</xref>]. Binding of both agonists is required for activation and results in a conformational change leading to the opening of a cation-selective transmembrane pore that catalyzes an influx of calcium and sodium at resting potentials [<xref rid="pone.0170818.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0170818.ref003" ref-type="bibr">3</xref>]. The GluN1 subunit is expressed ubiquitously throughout the brain, whereas the expression of four GluN2 subtypes (A-D) varies spatially and temporally. Messenger RNA for GluN2A and GluN2C is expressed after birth, and their expression levels appear to increase with age. By contrast, GluN2B and GluN2D subunits are expressed prenatally at an early stage of life, and decreases in most brain areas with age [<xref rid="pone.0170818.ref004" ref-type="bibr">4</xref>]. NMDARs play important roles not only in normal brain function, including learning, memory, synaptic plasticity, motor and sensory processes, and nervous system development, but also in a wide range of neurological diseases, such as epilepsy, Huntingtonâs disease, and Parkinsonâs disease, Alzheimerâs disease, autism, and schizophrenia [<xref rid="pone.0170818.ref005" ref-type="bibr">5</xref>â<xref rid="pone.0170818.ref012" ref-type="bibr">12</xref>].</p>
      <p>Recently, pathogenic NMDARs mutations have been identified in epilepsy, developmental delay, intellectual disability, autism, attention deficit hyperactivity (ADHD), and schizophrenia [<xref rid="pone.0170818.ref013" ref-type="bibr">13</xref>â<xref rid="pone.0170818.ref020" ref-type="bibr">20</xref>]. The <italic>GRIN2A</italic> gene encoding the GluN2A subunit has been suggested to constitute a locus for mutations in a subset of patients with early-onset seizures [<xref rid="pone.0170818.ref019" ref-type="bibr">19</xref>]. Several case-control studies have identified mutations in the <italic>GRIN2A</italic> gene in patients with different forms of epilepsy, including early-onset epileptic encephalopathy, continuous spike-and-waves during slow-wave sleep syndrome (CSWSS), Landau-Kleffner syndrome (LKS), and Rolandic epilepsy [<xref rid="pone.0170818.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0170818.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0170818.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0170818.ref021" ref-type="bibr">21</xref>â<xref rid="pone.0170818.ref024" ref-type="bibr">24</xref>].</p>
      <p>In this study, next generation sequencing identified a <italic>GRIN2A</italic> missense mutation c.2191G&gt;A (p.Asp731Asn, hereafter referred to as GluN2A-D731N) from a pediatric patient diagnosed with epilepsy and DD. The patientâs clinical features were summarized and compared with the two previously reported patients with the same mutation. The influence of the mutation on NMDA receptor function was evaluated here electrophysiologically <italic>in vitro</italic> by using two-electrode voltage clamp current recordings and whole cell voltage clamp current recordings.</p>
    </sec>
    <sec sec-type="materials|methods" id="sec006">
      <title>Materials and methods</title>
      <sec id="sec007">
        <title>Ethics statement</title>
        <p>Written informed consent was obtained from the parents of all the patients. This study was approved by the Peking University First Hospital Medical Ethics Committee. All data of this study were analyzed anonymously.</p>
      </sec>
      <sec id="sec008">
        <title>Patientâs information</title>
        <p>The patient with <italic>GRIN2A</italic> mutation was collected from the Department of Pediatrics, Peking University First Hospital in 2013. This patient was clinically diagnosed as having epilepsy and ID/DD of unknown origin. Nevertheless, it was strongly suspected that the etiology of these patientsâ diseases was genetic, as there was: (1) no definite perinatal brain injury; (2) no hypoxia, ischemia, infection of the central nervous system or cranial trauma; (3) no evidence of typical inherited metabolic disorders or specific neurodegenerative disorders based on clinical features, neuroimaging or blood/urinary metabolic diseases screening; (4) normal routine karyotyping.</p>
      </sec>
      <sec id="sec009">
        <title>Genetic analysis</title>
        <p>We constructed a custom-designed panel capturing the coding exons of 300 genes associated with epilepsy and IDDs, including <italic>GRIN2A</italic> [<xref rid="pone.0170818.ref025" ref-type="bibr">25</xref>]. This panel was synthesized using the Agilent SureSelect Target Enrichment technique, containing a total of 11,417 probes covering 1.285 Mbp. Targeted next generation sequencing (NGS) was subsequently performed on an Illumina GAIIx platform (Illumina, San Diego, CA, USA) using a paired-end sequencing of 110 bp to screen for mutations. Image analysis and base calling were performed by RTA software (real-time analysis, Illumina) and CASAVA software v1.8.2 (Illumina). After marking duplicate reads and filtering out reads of low base quality score using the Genome Analysis Tool kit (GATK), clean paired-end reads were aligned to GRCh27/hg19 using BWA software (Pittsburgh Supercomputing Center, Pittsburgh, PA, USA). In addition to insertion-deletions (indels) and single-nucleotide polymorphisms (SNPs) identified using the GATK, variants were annotated using ANNOVAR. At last, we performed validation and parental origin analyses for the mutation by conventional Sanger sequencing.</p>
      </sec>
      <sec id="sec010">
        <title>Site-directed mutagenesis, RNA synthesis, and injection</title>
        <p>All <italic>in vitro</italic> studies were conducted according to the guidelines of Emory University. Mutagenesis was performed using the <italic>QuikChange</italic> protocol with <italic>Pfu</italic> DNA polymerase (Stratagene La Jolla, CA, USA) to replicate the parental DNA strand with the desired mismatch incorporated into the primer. Methylated parental DNA was digested with Dpn I for 3 hours at 37Â°C and the nicked mutant DNA was transformed into TOP10 Competent Cells (Life Tech, Grand Islands, NY, USA). Bacteria were spun down and prepared using the Qiagen Qiaprep Spin Miniprep kit (Hilden, Germany). Sequences were verified through the mutated region using dideoxy DNA sequencing (Eurofins MWG Operon, Huntsville, AL, USA). The plasmid vector for wild type (WT) human GluN1-1a (hereafter GluN1) and GluN2A was pCI-neo [<xref rid="pone.0170818.ref022" ref-type="bibr">22</xref>] (GenBank accession codes: NP_015566, NP_00082).</p>
        <p>To investigate the effect of a single copy mutant on the channel function, the constructs of tri-heteromeric receptors were generated using rat GluN1-1a (hereafter GluN1) and GluN2A with modified C-terminal peptide tags. As described by Hansen et al. [<xref rid="pone.0170818.ref026" ref-type="bibr">26</xref>], two peptide tags (C1 and C2) were generated and allowed to form a coiled-coil interaction that masked the dilycine KKTN retention motif. These C-terminal retention signals were fused to the wild type and mutant GluN2A receptors to generate GluN2A-C1, GluN2A-C2, GluN2A-C1-D731N, GluN2A-C2- D731N. Only receptors with one copy of a C1 tag and one copy of a C2 tag will mask the endoplasmic reticulum retention signal and reach the cell membrane surface. Co-expressing with rat GluN1 with C1- and C2-tagged GluN2A yielded receptors with the following subunit combinations: GluN1/GluN2A-C1/GluN2A-C2 (referred to 2A/2A), GluN1/GluN2A-C1-D731N/GluN2A-C2 (referred to D731N/2A), and GluN1/GluN2A-C1-D731N/GluN2A-C2-D731N (referred to D731N/D731N).</p>
        <p>Complementary DNA (cDNA) was linearized using FastDigest (Thermo, Waltham, MA, USA) restriction digestion at 37Â°C for 1 hour. Complementary RNA (cRNA) was made from linearized cDNA for wild type and mutants using the mMessage mMachine T7 kit (Ambion, Austin, TX, USA). Injections of cRNA into <italic>Xenopus Laevis</italic> oocytes (Ecocyte, Austin, TX, USA) was performed as previously described [<xref rid="pone.0170818.ref027" ref-type="bibr">27</xref>]. Oocytes were held in Barthâs solution containing (in mM) 88 NaCl, 2.4 NaHCO<sub>3</sub>, 1 KCl, 0.33 Ca(NO<sub>3</sub>)<sub>2</sub>, 0.41 CaCl<sub>2</sub>, 0.82 MgSO<sub>4</sub>, 5 Tris/HCl (pH 7.4 with NaOH) supplemented with 100 Î¼g/mL gentamycin, 40 Î¼g/mL streptomycin, and 50 Î¼g/mL penicillin at 15â19Â°C. Injection of cRNA was done in a 1:2 GluN1:GluN2A ratio for the di-heteromeric receptors and 1:1:1 GluN1:GluN2A-C1:GluN2A-C2 ratio for the tri-heteromeric receptors by weight with injections totaling 5â10 ng of cRNA in water, with 50 nL injected per oocyte. Control experiments evaluating the escape of non-triheteromeric receptors from the ER retention were performed [<xref rid="pone.0170818.ref026" ref-type="bibr">26</xref>]. This evaluation estimated that &lt;3% of the current responses in the tri-heteromeric experiments were mediated by non-triheteromeric receptors.</p>
      </sec>
      <sec id="sec011">
        <title>Two-Electrode Voltage Clamp Current (TEVC) recordings</title>
        <p>Voltage clamp recordings were performed 2â4 days post-injection at room temperature (23Â°C). The extracellular recording solution contained (in mM) 90 NaCl, 1 KCl, 10 HEPES, 0.5 BaCl<sub>2</sub>, and 0.01 EDTA (pH 7.4 with NaOH). Solution exchange was computer controlled through an 8-valve positioner (Digital MVP Valve, Hamilton, CT, USA). Oocytes were placed in a dual track chamber that shared a single perfusion line, allowing simultaneous recording from two oocytes. All concentration-response solutions were made in the extracellular recording solution. Voltage control and data acquisition were performed with a two-electrode voltage-clamp amplifier (OC725, Warner Instruments, Hamden, CT, USA). The voltage electrode was filled with 0.3 M KCl and the current electrode with 3 M KCl. Oocytes were held under voltage clamp at -40 mV unless otherwise indicated. For the experiments with glutamate concentration â¥ 3 mM, osmolality was compensated for solutions with high concentrations of glutamate by adding sodium isethionate; the pH was corrected after addition of glutamate. Experiments assessing inhibition by extracellular Zn<sup>2+</sup> were performed in the presence of tricine (10 mM) at pH 7.3 with voltage held at -20 mV. ZnCl<sub>2</sub> solutions (10 mM) were made fresh daily in deionized nuclease-free water and added directly to recording solution to obtain the desired nominal Zn<sup>2+</sup> concentration<sup>25</sup>. Experiments assessing the sensitivity of the channel to Mg<sup>2+</sup> blockade were performed at a holding potential of -60 mV. The effects of Mg<sup>2+</sup>, proton, zinc, (+)MK801 maleate (R&amp;D Systems, Inc., Minneapolis, MN, USA), and MTSEA (2-aminoethyl methanethiosulfonate hydrobromide, Toronto Research Chemicals, Ontario, Canada) were evaluated on the current response to 4.0â30,000 Î¼M glutamate and 100 Î¼M glycine. For the experiments of MK801 and MTSEA, the EC<sub>50</sub> concentrations of glutamate were used to activate corresponding receptors. All chemicals were from Sigma-Aldrich unless otherwise stated.</p>
      </sec>
      <sec id="sec012">
        <title>Whole-cell voltage-clamp recordings from transfected HEK cells</title>
        <p>HEK293 cells (CRL 1573, ATCC, Manasas, VA, USA) were plated on glass coverslips coated with 0.1 mg/ml poly-D-lysine and cultured at 37Â°C in standard media (5% CO<sub>2</sub> in DMEM/GlutaMax with 10% fetal bovine serum and 10 U/ml penicillin-streptomycin). The calcium phosphate method [<xref rid="pone.0170818.ref028" ref-type="bibr">28</xref>] was used to co-transfect HEK293 cells with cDNA encoding GFP, GluN1, and GluN2A or GluN2A(D731N). After 24 hr, whole-cell voltage clamp current recordings were performed at 23Â°C at a holding potential of -60 mV using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, USA) in recording solution containing (in mM) 150 NaCl, 10 HEPES, 30 D-mannitol, 3 KCl, 1.0 CaCl<sub>2</sub>, and 0.01 EDTA (pH 7.4). Recordings were made by recording electrodes (3â5 MÎ©) filled with (in mM) 110 D-gluconate, 110 CsOH, 30 CsCl, 5 HEPES, 4 NaCl, 0.5 CaCl<sub>2</sub>, 2 MgCl<sub>2</sub>, 5 BAPTA, 2 NaATP, and 0.3 NaGTP (pH 7.35). Rapid solution exchange was achieved by using a two-barrel theta glass pipette controlled by a piezoelectric translator (Siskiyou Corporation, Grants Pass, OR, USA). Open-tip solution exchange time was &lt; 1 ms. The data were acquired using Clampex 10 (Molecular Devices, Sunnyvale, CA, USA). Time constants describing the deactivation time course were determined using ChanneLab (Synaptosoft, Decatur, GA, USA) to fit a two-component exponential function to the current response time course following glutamate removal,
<disp-formula id="pone.0170818.e001"><alternatives><graphic xlink:href="pone.0170818.e001.jpg" id="pone.0170818.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="M1"><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>F</mml:mi><mml:mi>A</mml:mi><mml:mi>S</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>Ã</mml:mo><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mo>â</mml:mo><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">Ï</mml:mi></mml:mrow><mml:mrow><mml:mi>F</mml:mi><mml:mi>A</mml:mi><mml:mi>S</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>L</mml:mi><mml:mi>O</mml:mi><mml:mi>W</mml:mi></mml:mrow></mml:msub><mml:mo>Ã</mml:mo><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mo>â</mml:mo><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">Ï</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>L</mml:mi><mml:mi>O</mml:mi><mml:mi>W</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:math></alternatives><label>Equation-1</label></disp-formula>
where <italic>Amp</italic><sub><italic>FAST</italic></sub> and <italic>Amp</italic><sub><italic>SLOW</italic></sub> are the amplitude of the fast and slow components.</p>
      </sec>
    </sec>
    <sec id="sec013">
      <title>Data and statistical analysis</title>
      <p>The EC<sub>50</sub> value is the concentration of agonist that elicits a half maximal excitatory response, and was determined by
<disp-formula id="pone.0170818.e002"><alternatives><graphic xlink:href="pone.0170818.e002.jpg" id="pone.0170818.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="M2"><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mn>100</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">H</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>Equation-2</label></disp-formula>
where <italic>nH</italic> is the Hill slope of the response curve. The IC<sub>50</sub> value is the concentration of antagonist that elicits a half-maximal inhibitory response, and was calculated using
<disp-formula id="pone.0170818.e003"><alternatives><graphic xlink:href="pone.0170818.e003.jpg" id="pone.0170818.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="M3"><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>100</mml:mn><mml:mi>%</mml:mi><mml:mo>â</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">H</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi></mml:math></alternatives><label>Equation-3</label></disp-formula>
where <italic>minimum</italic> is the residual response at saturating concentrations of inhibitor (Mg<sup>2+</sup>, protons, or Zn<sup>2+</sup>).</p>
      <p>The channel open probability (<italic>P</italic><sub><italic>OPEN</italic></sub>) of the mutant receptors was assessed using the kinetics of MK801 inhibition by TEVC recordings. The onset of MK801 inhibition was fitted to a single exponential function (ChanneLab, Synaptosoft, Decatur, GA, USA) to determine <italic>tau</italic><sub><italic>on</italic></sub> according to
<disp-formula id="pone.0170818.e004"><alternatives><graphic xlink:href="pone.0170818.e004.jpg" id="pone.0170818.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="M4"><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mo>Ã</mml:mo><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mo>â</mml:mo><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:math></alternatives><label>Equation-4</label></disp-formula>
<italic>P</italic><sub><italic>OPEN</italic></sub> was estimated from
<disp-formula id="pone.0170818.e005"><alternatives><graphic xlink:href="pone.0170818.e005.jpg" id="pone.0170818.e005g" mimetype="image" position="anchor" orientation="portrait"/><mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="M5"><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>Ã</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>Equation-5</label></disp-formula>
Assuming that the binding of MK801 is irreversible over the time course of the experiment, the microscopic association rate for MK801, <italic>k</italic><sub><italic>on</italic></sub>, is 1/(<italic>tau</italic><sub><italic>on</italic></sub>
<italic>Ã</italic> [<italic>concentration</italic>]), where <italic>concentration</italic> was 0.2 Î¼M, and P<sub>OPEN</sub> for WT receptors was taken to be 0.278 for di-heteromeric receptors (WT 2A; calculated P<sub>OPEN</sub>: 0.278 Â± 0.017 from 252 Â± 16% of MTSEA potentiation by Equation-<xref ref-type="disp-formula" rid="pone.0170818.e006">6</xref> below, n = 13) and 0.370 for tri-heteromeric receptors (WT 2A/2A; Supplemental Fig 2 in [<xref rid="pone.0170818.ref029" ref-type="bibr">29</xref>]) in the presence of saturating concentrations of agonists (â¥ 100 Î¼M for both glutamate and glycine)</p>
      <p>The channel open probability was also evaluated and calculated by the degree of MTSEA potentiation on the currents evoked by EC<sub>50</sub> concentrations of glutamate and 100 Î¼M glycine by using [<xref rid="pone.0170818.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0170818.ref031" ref-type="bibr">31</xref>]:
<disp-formula id="pone.0170818.e006"><alternatives><graphic xlink:href="pone.0170818.e006.jpg" id="pone.0170818.e006g" mimetype="image" position="anchor" orientation="portrait"/><mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="M6"><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>Î³</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>T</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>Î³</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mi>O</mml:mi><mml:mi>N</mml:mi><mml:mi>T</mml:mi><mml:mi>R</mml:mi><mml:mi>O</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo><mml:mo>Ã</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mi>P</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:math></alternatives><label>Equation-6</label></disp-formula>
where <italic>Potentiation</italic> is the current after MTSEA treatment divided by the current before treatment and Î³ is the chord conductance measured before and after MTSEA treatment.</p>
      <p>Statistical significance was computed using unpaired <italic>t</italic> test (two-tailed) or one way ANOVA with <italic>post hoc</italic> Tukey test, with p &lt; 0.05 considered significant. Data are presented as mean Â± standard error of the mean (SEM). Error bars represent SEM unless otherwise stated.</p>
    </sec>
    <sec sec-type="results" id="sec014">
      <title>Results</title>
      <sec id="sec015">
        <title>Identification of GluN2A(D731N) mutation</title>
        <p>We identified a <italic>de novo</italic> missense mutation c.2191G&gt;A (p.Asp731Asn, D731N; <xref ref-type="fig" rid="pone.0170818.g001">Fig 1A</xref>) in a patient with focal epilepsy and acquired epileptic aphasia, a heterozygous <italic>GRIN2A</italic> mutation in a portion of the gene that is intolerant to change. The result is an aspartic acid to asparagine missense mutation at residue 731 in the extracellular agonist-binding domain (ABD) of the GluN2A subunit. This area is highly conserved across different vertebrate species as well as among all of the other NMDAR subunits (<xref ref-type="fig" rid="pone.0170818.g001">Fig 1B</xref>), indicating a possible important role in NMDAR function. The segment of the polypeptide chain harboring residue 731, often referred to as the S2 region, largely forms membrane-proximal half of the bi-lobed clamshell responsible for binding agonist, and is composed of the polypeptide chain between the M3 and M4 transmembrane domains (<xref ref-type="fig" rid="pone.0170818.g001">Fig 1C</xref>). The residue Asp at position 731 resides within the glutamate binding pocket (<xref ref-type="fig" rid="pone.0170818.g001">Fig 1D</xref>), and the substitution of Asn at this position may interfere glutamate ligand binding.</p>
        <fig id="pone.0170818.g001" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0170818.g001</object-id>
          <label>Fig 1</label>
          <caption>
            <title>Genetic and protein changes of <italic>GRIN2A</italic> and GluN2A.</title>
            <p>(<bold>A</bold>) Family pedigree and genotypes (indicated by *) reveal a <italic>de novo</italic> mutation (affected proband is indicated by arrow; parentage was confirmed by Sanger sequencing). (<bold>B</bold>) Schematic representation of GluN2A subunit (asterisk indicates the position of the D731N mutation). The residue aspartic acid at position 731 is highly conserved across vertebrate species, and other GluN subunits. (<bold>C</bold>) A homology model of GluN1/GluN2A complex built from the GluN2B crystallographic data [<xref rid="pone.0170818.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0170818.ref033" ref-type="bibr">33</xref>] with Asp731 shown as spacefill in red. The red asterisk in the cartoon illustrating the domain arrangement of an individual GluN subunit (right panel) shows the position of Asp731 in the agonist-binding domain (S2, ABD). Panel <bold>D</bold> shows glutamate binding pocket depicting the position of D731 (in GREEN) and D731N (in RED) in the GluN2A ABD structure in complex with ligand glutamate (in CYAN).</p>
          </caption>
          <graphic xlink:href="pone.0170818.g001"/>
        </fig>
      </sec>
      <sec id="sec016">
        <title>Patient information</title>
        <p>The patient was an 11-year-old girl with partial seizures that started at four years of age, with seizures restricted to periods of sleep. Until now, she has been treated with four antiepileptic drugs (AEDs), including valproate and oxcarbazepine, which had no obvious effect. In addition, levetiracetam and clonazepam partially controlled the seizures. She manifested developmental delay from one-year-old and started motor and cognitive function regression, especially verbal dyspraxia at four-year-old after seizures happened. She also suffered from paroxysmal weakness of her right lower limb and gait abnormality. Her prenatal history was normal and neurological examination was unremarkable. Her electroencephalograph (EEG) recordings (at 6 years) showed that background activities were slow, and that spike and spike-wave complexes were present in bilateral rolandic regions, with a significant increase during sleep; discharge index was about 85% in non-rapid eye movement (NREM) sleep (<xref ref-type="fig" rid="pone.0170818.g002">Fig 2</xref>). Her cranial magnetic resonance imaging (MRI) was normal (data not shown). Two additional patients with the same missense mutation have separately been reported [<xref rid="pone.0170818.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0170818.ref034" ref-type="bibr">34</xref>], however no functional analysis on the effects of this mutation were performed on human NMDARs. Thus, a total of three unrelated non-familial patients that have been identified with the same missense mutation and a similar, if not identical, presentation of symptoms including seizures, cognitive deficits, and motor deficits (<xref rid="pone.0170818.t001" ref-type="table">Table 1</xref>).</p>
        <fig id="pone.0170818.g002" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0170818.g002</object-id>
          <label>Fig 2</label>
          <caption>
            <title>EEG of patient 6245 at 6y7m.</title>
            <p>(A) During awake period, spike and spike-wave complexes (arrow heads) in Rolandic region, more obvious on the left side (blue). (B) During sleep period, NREM (non-rapid eye movement) index was about 85%.</p>
          </caption>
          <graphic xlink:href="pone.0170818.g002"/>
        </fig>
        <table-wrap id="pone.0170818.t001" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0170818.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Summary of patients' information.</title>
          </caption>
          <alternatives>
            <graphic id="pone.0170818.t001g" xlink:href="pone.0170818.t001"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="center" rowspan="1" colspan="1">Â </th>
                  <th align="center" rowspan="1" colspan="1">Patient 1</th>
                  <th align="center" rowspan="1" colspan="1">Patient 2</th>
                  <th align="center" rowspan="1" colspan="1">Patient 3</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Mutation</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1"><italic>De novo</italic> GRIN2A c.2191G&gt;A (p.Asp731Asn)</td>
                  <td align="center" rowspan="1" colspan="1">Inherited GRIN2A c.2191G&gt;A (p.Asp731Asn)</td>
                  <td align="center" rowspan="1" colspan="1"><italic>De novo</italic> GRIN2A c.2191G&gt;A (p.Asp731Asn)</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Family History</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">None</td>
                  <td align="center" rowspan="1" colspan="1">Same mutation in mother only had VD</td>
                  <td align="center" rowspan="1" colspan="1">Same mutation in daughter</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Diagnoses</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">aRE, VD</td>
                  <td align="center" rowspan="1" colspan="1">aRE, VD</td>
                  <td align="center" rowspan="1" colspan="1">LKS</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Seizure Type</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">PS</td>
                  <td align="center" rowspan="1" colspan="1">GTCS</td>
                  <td align="center" rowspan="1" colspan="1">PS, GTCS (resolved in late childhood)</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Onset Age</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">4 yrs</td>
                  <td align="center" rowspan="1" colspan="1">2 yrs</td>
                  <td align="center" rowspan="1" colspan="1">5 yrs</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>ID/DD</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">Motor and cognitive developmental delay, VD</td>
                  <td align="center" rowspan="1" colspan="1">Intellectual, motor and cognitive regression, Psychomotor and language delay</td>
                  <td align="center" rowspan="1" colspan="1">N/A</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>EEG</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">Discharges in rolandic region, ESES</td>
                  <td align="center" rowspan="1" colspan="1">CTS</td>
                  <td align="center" rowspan="1" colspan="1">Sharp slow-wave complexes in temporal lobes</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>MRI/CT</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">normal</td>
                  <td align="center" rowspan="1" colspan="1">Â N/A</td>
                  <td align="center" rowspan="1" colspan="1">normal</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Source</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">this study</td>
                  <td align="center" rowspan="1" colspan="1">Lesca et al., Nat Genet 2013</td>
                  <td align="center" rowspan="1" colspan="1">Dyment et al., Clin Genet 2015</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="t001fn001">
              <p>aRE: atypical Rolandic Epilepsy; CTS: cerebrotemporal spikes; ESES: Electrical Status Epilepticus in sleep; GTCS: General tonic-clonic seizures; LKS: Landau-Kleffner Syndrome; N/A: not available; PS: partial seizures; VD: verbal dyspraxia.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="sec017">
        <title>GluN2A(D731N) mutation changes agonist glutamate potency</title>
        <p>Two-electrode voltage clamp current recordings from <italic>Xenopus laevis</italic> oocytes (<xref ref-type="fig" rid="pone.0170818.g003">Fig 3A and 3B</xref><bold>)</bold> were performed to evaluate the effect of the GluN2A mutation on NMDAR function. Concentration-response curves (<xref ref-type="fig" rid="pone.0170818.g003">Fig 3</xref>) were generated for the endogenous NMDAR co-agonists glutamate and glycine to evaluate whether the mutation changes agonist potency. The analyses of these data show that the GluN2A(D731N)-containing NMDA receptors had a significantly lower glutamate potency, with the EC<sub>50</sub> value being increased from 3.7 Î¼M in WT GluN2A receptors to about 13.7 mM in GluN2A(D731N)-containing NMDA receptors (<xref ref-type="fig" rid="pone.0170818.g003">Fig 3C</xref>; <xref rid="pone.0170818.t002" ref-type="table">Table 2</xref>) when the concentration-response curves were fitted (dash lines in <xref ref-type="fig" rid="pone.0170818.g003">Fig 3</xref>) with predicted maximal response since the saturating glutamate concentrations are unknown. There is also a modest, but significant, decrease in glycine potency from an EC<sub>50</sub> value of 1.0 Î¼M in WT NMDAR receptors to 1.7 Î¼M in GluN2A (D731N)-containing NMDARs (<xref ref-type="fig" rid="pone.0170818.g003">Fig 3C and 3D</xref>; <xref rid="pone.0170818.t002" ref-type="table">Table 2</xref>). These data suggest that GluN2A(D731N) mutation decreases the potency of glutamate by over 3,000-fold, suggesting high concentrations of glutamate are needed in the brain to activate the NMDARs harboring this mutation.</p>
        <fig id="pone.0170818.g003" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0170818.g003</object-id>
          <label>Fig 3</label>
          <caption>
            <title>GluN2A(D731N) reduces the agonist potency.</title>
            <p>(<bold>A,B</bold>) Representative TEVC recordings obtained from oocytes expressing WT GluN1/GluN2A (WT 2A) receptors (<bold>A</bold>) and GluN1/GluN2A(D731N) (2A-D731N) receptors (<bold>B</bold>) in which the currents were evoked by increasing concentrations (Î¼M) of glutamate (in the presence of 100 Î¼M glycine) at the holding potential of -40 mV. (<bold>C,D</bold>) Composite concentration-response curves of glutamate and glycine for di-heteromeric receptors GluN1/GluN2A (WT 2A) and GluN1/GluN2A-D731N (2A-D731N). (<bold>E,F</bold>) Composite concentration-response curves of glutamate and glycine for tri-heteromeric receptors GluN1/GluN2A/GluN2A (2A/2A), GluN1/GluN2A(D731N)/GluN2A (D731N/2A) and GluN1/GluN2A(D731N)/GluN2A(D731N) (D731N/D731N). (<bold>C,E</bold>) The composite glutamate (in the presence of 100 Î¼M glycine) concentration-response curves reveal a significant decrease in glutamate potency in both di-heteromeric (<bold>C</bold>) and tri-heteromeric (<bold>E</bold>) GluN2A(D731N)-containing NMDARs compared to wild type receptors. A single copy D731N-containing receptor (D731N/2A) (<bold>E</bold>) showed an intermediate but a dominantly negative effect on glutamate potency. The traces for D731N-contianing receptors (dash lines in panels <bold>C</bold> and <bold>E</bold>) were fitted by predicted glutamate concentrations of maximal responses. (<bold>D,F</bold>) The composite glycine (in the presence of 3â30 mM glutamate) concentration-response curves indicate a mild, but significantly reduced glycine potency in both di-heteromeric (<bold>D</bold>) and tri-heteromeric (<bold>F</bold>) GluN2A(D731N) receptors. Error bars are SEM, and are shown when larger than symbol size.</p>
          </caption>
          <graphic xlink:href="pone.0170818.g003"/>
        </fig>
        <table-wrap id="pone.0170818.t002" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0170818.t002</object-id>
          <label>Table 2</label>
          <caption>
            <title>Summary of pharmacological data for GluN2A(D731N).</title>
          </caption>
          <alternatives>
            <graphic id="pone.0170818.t002g" xlink:href="pone.0170818.t002"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="1" colspan="1">Â </th>
                  <th align="center" colspan="2" rowspan="1">di-heteromeric receptors</th>
                  <th align="center" colspan="3" rowspan="1">tri-heteromeric receptors</th>
                </tr>
                <tr>
                  <th align="left" rowspan="1" colspan="1">Â </th>
                  <th align="center" rowspan="1" colspan="1">WT 2A</th>
                  <th align="center" rowspan="1" colspan="1">2A-D731N</th>
                  <th align="center" rowspan="1" colspan="1">WT 2A/2A</th>
                  <th align="center" rowspan="1" colspan="1">D731N/2A</th>
                  <th align="center" rowspan="1" colspan="1">D731N/D731N</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="center" rowspan="1" colspan="1"><bold>Glutamate, EC</bold><sub><bold>50</bold></sub>
<bold>(n)</bold></td>
                  <td align="center" rowspan="1" colspan="1">3.7 Â± 0.1 (7)</td>
                  <td align="center" rowspan="1" colspan="1">13,655 Â± 199 (11) <xref ref-type="table-fn" rid="t002fn002"><sup>Â¥</sup></xref><xref ref-type="table-fn" rid="t002fn003">*</xref></td>
                  <td align="center" rowspan="1" colspan="1">5.7 Â± 0.5 (10)</td>
                  <td align="center" rowspan="1" colspan="1">6,451 Â± 260 (16) <xref ref-type="table-fn" rid="t002fn002"><sup>Â¥</sup></xref>
<xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td>
                  <td align="center" rowspan="1" colspan="1">30,469 Â± 438 (11) <xref ref-type="table-fn" rid="t002fn002"><sup>Â¥</sup></xref>
<xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref>
<xref ref-type="table-fn" rid="t002fn005"><sup>%</sup></xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1"><bold>Glycine, EC</bold><sub><bold>50</bold></sub>
<bold>(n)</bold></td>
                  <td align="center" rowspan="1" colspan="1">1.1 Â± 0.1 (10)</td>
                  <td align="center" rowspan="1" colspan="1">1.7 Â± 0.2 (10)<xref ref-type="table-fn" rid="t002fn003">*</xref></td>
                  <td align="center" rowspan="1" colspan="1">1.3 Â± 0.1 (8)</td>
                  <td align="center" rowspan="1" colspan="1">2.1 Â± 0.1 (12) <xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td>
                  <td align="center" rowspan="1" colspan="1">2.0 Â± 0.2 (8) <xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Proton, IC</bold>
                    <sub>
                      <bold>50</bold>
                    </sub>
                  </td>
                  <td align="center" rowspan="1" colspan="1">6.8 (5)</td>
                  <td align="center" rowspan="1" colspan="1">7.3 (6)</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Proton, % (n)</bold>
                    <xref ref-type="table-fn" rid="t002fn005">
                      <sup>
                        <bold>Â£</bold>
                      </sup>
                    </xref>
                  </td>
                  <td align="center" rowspan="1" colspan="1">54 Â± 1.4 (10)</td>
                  <td align="center" rowspan="1" colspan="1">34 Â± 1.7 (8)<xref ref-type="table-fn" rid="t002fn003">*</xref></td>
                  <td align="center" rowspan="1" colspan="1">59 Â± 1.8 (11)</td>
                  <td align="center" rowspan="1" colspan="1">37 Â± 1.8 (8) <xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td>
                  <td align="center" rowspan="1" colspan="1">33 Â± 3.9 (8) <xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1"><bold>Zinc, IC</bold><sub><bold>50</bold></sub>
<bold>(n)</bold></td>
                  <td align="center" rowspan="1" colspan="1">87 Â± 12 (5)</td>
                  <td align="center" rowspan="1" colspan="1">20 Â± 5.6 (8)<xref ref-type="table-fn" rid="t002fn003">*</xref></td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Zinc, max% (n)</bold>
                    <xref ref-type="table-fn" rid="t002fn006">
                      <sup>
                        <bold>$</bold>
                      </sup>
                    </xref>
                  </td>
                  <td align="center" rowspan="1" colspan="1">36 Â± 1.5 (5)</td>
                  <td align="center" rowspan="1" colspan="1">58 Â± 2.2 (8)<xref ref-type="table-fn" rid="t002fn003">*</xref></td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1"><bold>Mg</bold><sup><bold>2+</bold></sup><bold>, IC</bold><sub><bold>50</bold></sub>
<bold>(n)</bold><xref ref-type="table-fn" rid="t002fn007"><sup><bold>&amp;</bold></sup></xref></td>
                  <td align="center" rowspan="1" colspan="1">31 Â± 4.1 (20)</td>
                  <td align="center" rowspan="1" colspan="1">25 Â± 4.1 (15)</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="t002fn001">
              <p>The data were generated by TEVC recordings on <italic>Xenopus</italic> oocytes and were expressed as mean Â± s.e.m. (n) is the number of cells recorded from.</p>
            </fn>
            <fn id="t002fn002">
              <p><sup>Â¥</sup> fitted EC<sub>50</sub> values by predicted glutamate concentrations of maximal responses</p>
            </fn>
            <fn id="t002fn003">
              <p>* p &lt; 0.01, compared with WT 2A, unpaired t-test</p>
            </fn>
            <fn id="t002fn004">
              <p><sup>#</sup> p &lt; 0.01 compared with WT 2A/2A</p>
            </fn>
            <fn id="t002fn005">
              <p><sup>%</sup> p &lt; 0.01 compared with D731N/2A, one way ANOVA, <italic>post hoc</italic> Tukey test</p>
            </fn>
            <fn id="t002fn006">
              <p><sup>Â£</sup> percentage current at pH 6.8 compared to the pH 7.6</p>
            </fn>
            <fn id="t002fn007">
              <p><sup>$</sup> maximal inhibition at 300 nM Zn<sup>2+</sup></p>
            </fn>
            <fn id="t002fn008">
              <p><sup>&amp;</sup> holding at -60 mV</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Since the mutation in these patients is heterozygous and the functional NMDAR complex contains two copies of GluN2 subunit, we expect some NMDARs in these individuals may have a single copy of mutant GluN2A(D731N). We therefore engineered a pair of modified GluN2A subunits that contain complementary sets of coiled-coil domains followed by an endoplasmic reticulum retention signal to control receptor trafficking and subunit composition on the cell surface [<xref rid="pone.0170818.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0170818.ref034" ref-type="bibr">34</xref>]. We generated receptors containing 0, 1 and 2 copies of the GluN2A(D731N) on the cell surface and repeated the experiments that establish the concentration-effect relationship to investigate the effects of a single copy of GluN2A(D731N) on agonist potency. The data showed that a single copy of GluN2A(D731N) produced an intermediate, but strong decrease in glutamate potency (2A/2A: 5.7 Â± 0.5 Î¼M; D731N /2A: 6,451 Â± 260 Î¼M; D731N/D731N: 30,469 Â± 438 Î¼M) (<xref ref-type="fig" rid="pone.0170818.g003">Fig 3F</xref>; <xref rid="pone.0170818.t002" ref-type="table">Table 2</xref>). Again, the concentration-response curves were fitted (dash lines in <xref ref-type="fig" rid="pone.0170818.g003">Fig 3F</xref>) with predicted maximal response since the saturating glutamate concentrations could not be determined. Similar to the di-heteromeric mutant receptors (2A-D731N), NMDARs that contained one or two copies of GluN2A(D731N) showed a mild, but significant reduction in glycine potency (2A/2A: 1.3 Â± 0.1 Î¼M; D731N /2A: 2.1 Â± 0.1 Î¼M; D731N/D731N: 2.0 Â± 0.2 Î¼M) (<xref ref-type="fig" rid="pone.0170818.g003">Fig 3F</xref>; <xref rid="pone.0170818.t002" ref-type="table">Table 2</xref>). These results confirm that a single copy of GluN2A(D731N)-containing NMDARs can significantly alter receptor function.</p>
      </sec>
      <sec id="sec018">
        <title>GluN2A(D731N) mutation changes sensitivity to negative allosteric modulators</title>
        <p>Negative regulation by endogenous extracellular magnesium, zinc and protons is an important feature of NMDAR function [<xref rid="pone.0170818.ref001" ref-type="bibr">1</xref>]. The sensitivity of the mutant receptors to extracellular Mg<sup>2+</sup>, Zn<sup>2+</sup>, and H<sup>+</sup> was evaluated by generating concentration-response curves using two electrode voltage clamp current recordings to calculate the concentration required to produce half maximal inhibition of responses (IC<sub>50</sub>).</p>
        <p>Analysis revealed that GluN2A(D731N)-containing receptors significantly increase the proton sensitivity as measured by IC<sub>50</sub> corresponding to pH 7.3 for the mutant, compared to pH 6.8 of WT GluN2A (<bold><xref ref-type="fig" rid="pone.0170818.g004">Fig 4A</xref>; <xref rid="pone.0170818.t002" ref-type="table">Table 2</xref></bold>). The di-heteromeric mutant receptors showed significantly less current remaining at pH 6.8 compared to pH 7.6 (34%) than the WT receptors (54%; <bold><xref ref-type="fig" rid="pone.0170818.g004">Fig 4B</xref>; <xref rid="pone.0170818.t002" ref-type="table">Table 2</xref></bold>), indicating an enhanced proton inhibition on the mutant receptors. One-copy and two-copy D731N-containing NMDARs also showed significantly less current remaining at pH 6.8 compared to pH 7.6 than the WT receptors (2A/2A: 59%, D731N/2A: 37%, and D731N/2A: 33%). In addition, the GluN2A(D731N)-containing receptors showed an increased degree of maximal inhibition by 300 nM Zn<sup>2+</sup>, which was 58% in GluN2A(D731N) compared to 36% for the WT receptors (<xref ref-type="fig" rid="pone.0170818.g004">Fig 4C</xref>; <xref rid="pone.0170818.t002" ref-type="table">Table 2</xref>). Mg<sup>2+</sup> potency was not significantly affected by GluN2A(D731N) (<xref ref-type="fig" rid="pone.0170818.g004">Fig 4D</xref>; <xref rid="pone.0170818.t002" ref-type="table">Table 2</xref>). Altogether, these results suggest that lower concentrations of negative allosteric modulators Zn<sup>2+</sup> and H<sup>+</sup> can inhibit the mutant NMDAR receptors harboring D731N compared to the WT receptors, further contributing to NMDAR hypofunction.</p>
        <fig id="pone.0170818.g004" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0170818.g004</object-id>
          <label>Fig 4</label>
          <caption>
            <title>GluN2A(D731N) enhances sensitivity to endogenous proton and zinc ions.</title>
            <p>(<bold>A</bold>) The composite proton concentration-response curves show an enhanced sensitivity of the GluN2A(D731N)-containing receptors to proton compared to the WT NMDA receptors; the abscissa shows hydrogen ion activity. (<bold>B</bold>) Summary of proton sensitivity of WT GluN2A and mutant receptors, evaluated by current ratio at pH 6.8 to pH 7.6 (in the presence of 30 mM glutamate and 100 Î¼M glycine). Di-heteromeric (h2A-D731N), one-copy and two-copy mutant tri-heteromeric (D731N/2A and D731N/D731N) receptors show a decreased current ratio, indicating enhanced proton sensitivity. (<bold>C</bold>) The composite zinc concentration-response curves show an enhanced sensitivity of the GluN2A(D731N)-containing receptors to zinc compared to the WT NMDA receptors. (<bold>D</bold>) Composite Mg<sup>2+</sup> concentration-response curves for di-heteromeric receptors indicate a similar Mg<sup>2+</sup> inhibition of GluN2A(D731N)-containing receptors. The data were generated by TEVC recordings on <italic>Xenopus</italic> oocyte at holding potential of -40 mV for proton concentration-response curves, and -20 mV for zinc, and -60 mV for Mg<sup>2+</sup> concentration-response curves. Fitted parameters are in <xref rid="pone.0170818.t002" ref-type="table">Table 2</xref>.</p>
          </caption>
          <graphic xlink:href="pone.0170818.g004"/>
        </fig>
      </sec>
      <sec id="sec019">
        <title>GluN2A(D731N) mutation changes synaptic-like response time course</title>
        <p>The response time course following rapid removal of glutamate from NMDARs has been suggested to control the time-course of the NMDAR component of the EPSC (excitatory postsynaptic current) [<xref rid="pone.0170818.ref035" ref-type="bibr">35</xref>]. To evaluate the effects of GluN2A(D731N) on the deactivation time course, we measured current responses following glutamate removal using a rapid solution exchange system in whole cell voltage clamp current recordings from transiently transfected HEK293 cells expressing WT GluN1/GluN2A or GluN1/GluN2A(D731N). GluN2A(D731N) significantly reduced amplitude of current response to 1.5 sec application (prolonged application) of 30 mM glutamate in the presence of 100 Î¼M glycine (5.1 pA/pF vs. 235 pA/pF of WT; <xref ref-type="fig" rid="pone.0170818.g005">Fig 5A</xref>; <xref rid="pone.0170818.t003" ref-type="table">Table 3</xref>), which is consistent with the effect of this mutation on receptor surface trafficking [<xref rid="pone.0170818.ref020" ref-type="bibr">20</xref>]. The mutant receptors indicated a shortened glutamate deactivation time course fitted by two exponential components, with a weighted Ï<sub>w</sub> of 18 ms compared to 72 ms for WT GluN1/GluN2A (p &lt; 0.01, unpaired t-test; <xref ref-type="fig" rid="pone.0170818.g005">Fig 5B</xref>; <xref rid="pone.0170818.t003" ref-type="table">Table 3</xref>). Charge transfer during synaptic transmission can be determined from the integral of experimentally recorded EPSCs, which can be approximated by an instantaneously rising and exponentially decaying function. The integral of this function is the product of the amplitude and the weighted time constant describing the exponential decay. We estimate the synaptic charge transfer by using the product of the response amplitude and deactivation time courses, which was markedly decreased by over 180-fold for GluN2A(D731N) compared to wild type GluN2A (<xref rid="pone.0170818.t003" ref-type="table">Table 3</xref>). To mimic synaptic events, we also measured current responses by briefly moving the cell into the agonist solution for 5 milliseconds (brief application). Similar to the prolonged (1.5 sec) application of glutamate, GluN2A(D731N) had a faster deactivation time course with a Ï<sub>W</sub> of 13 Â± 2.0 ms compared to 55 Â± 8.4 ms for WT GluN2A (p &lt; 0.01, unpaired t-test; <xref ref-type="fig" rid="pone.0170818.g005">Fig 5C and 5D</xref>). These data suggest NMDARs that contained GluN2A(D731N) have a shortened deactivation response time course, and thus a shortened time course of the NMDAR component of the EPSC at synapses.</p>
        <fig id="pone.0170818.g005" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0170818.g005</object-id>
          <label>Fig 5</label>
          <caption>
            <title>GluN2A(D731N) decreases current amplitudes and shortens synaptic-like response time course.</title>
            <p>The representative current response time course was generated by the whole cell voltage clamp recording (V<sub>HOLD</sub> -60 mV) of GluN1/GluN2A (WT 2A, in BLACK) and GluN1/GluN2A-D731N (2A-D731N, in RED) receptor responses to rapid application of long (1.5 sec) (<bold>A,B</bold>) and brief (5 ms) (<bold>C,D</bold>) application of 30 mM glutamate. Panels <bold>B</bold> and <bold>D</bold> showed normalized responses to the WT response at the moment glutamate were removed. The mutant D731N-containing receptors showed an accelerated deactivation time course (<italic>right panel</italic> in <bold>B,D</bold>). Saturating glycine (100 Î¼M) was present in all of solutions. Fitted parameters describing the response time course are given in <bold><xref rid="pone.0170818.t003" ref-type="table">Table 3</xref>.</bold></p>
          </caption>
          <graphic xlink:href="pone.0170818.g005"/>
        </fig>
        <table-wrap id="pone.0170818.t003" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0170818.t003</object-id>
          <label>Table 3</label>
          <caption>
            <title>Summary of response time course for GluN2A(D731N).</title>
          </caption>
          <alternatives>
            <graphic id="pone.0170818.t003g" xlink:href="pone.0170818.t003"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="1" colspan="1">Â </th>
                  <th align="center" rowspan="1" colspan="1">WT 2A</th>
                  <th align="center" rowspan="1" colspan="1">2A-D731N</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Amplitude (peak, pA/pF)</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">235 Â± 46</td>
                  <td align="center" rowspan="1" colspan="1">5.1 Â± 1.1 <xref ref-type="table-fn" rid="t003fn003">*</xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Amplitude (SS, pA/pF)</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">126 Â± 28</td>
                  <td align="center" rowspan="1" colspan="1">4.8 Â± 1.0 <xref ref-type="table-fn" rid="t003fn003">*</xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>ISS / IPEAK</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">0.56 Â± 0.01</td>
                  <td align="center" rowspan="1" colspan="1">0.94 Â± 0.01 <xref ref-type="table-fn" rid="t003fn003">*</xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>10â90% Rise time (ms)</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">4.9 Â± 0.4</td>
                  <td align="center" rowspan="1" colspan="1">17 Â± 2.2 <xref ref-type="table-fn" rid="t003fn003">*</xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">Ï<sub><bold>FAST</bold></sub>
<bold>deactivation (ms)</bold></td>
                  <td align="center" rowspan="1" colspan="1">41 Â± 3.7</td>
                  <td align="center" rowspan="1" colspan="1">15 Â± 2.4 <xref ref-type="table-fn" rid="t003fn003">*</xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">Ï<sub><bold>SLOW</bold></sub>
<bold>deactivation (ms)</bold></td>
                  <td align="center" rowspan="1" colspan="1">384 Â± 96</td>
                  <td align="center" rowspan="1" colspan="1">37 Â± 12 <xref ref-type="table-fn" rid="t003fn003">*</xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1"><bold>%</bold>Ï<sub><bold>FAST</bold></sub>
<bold>deactivation</bold></td>
                  <td align="center" rowspan="1" colspan="1">81 Â± 6.5</td>
                  <td align="center" rowspan="1" colspan="1">74 Â± 6.2 <xref ref-type="table-fn" rid="t003fn003">*</xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">Ï<sub><bold>W</bold></sub>
<bold>deactivation (ms)</bold><xref ref-type="table-fn" rid="t003fn002"><sup><bold>$</bold></sup></xref></td>
                  <td align="center" rowspan="1" colspan="1">72 Â± 9.2</td>
                  <td align="center" rowspan="1" colspan="1">18 Â± 2.3 <xref ref-type="table-fn" rid="t003fn003">*</xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>Charge transfer, pA x ms/pF</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">16,984</td>
                  <td align="center" rowspan="1" colspan="1">92 <xref ref-type="table-fn" rid="t003fn003">*</xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>n</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">12</td>
                  <td align="center" rowspan="1" colspan="1">11</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="t003fn001">
              <p>The data were generated by whole cell voltage clamp current recordings on transfected HEK293 cells and were expressed as mean Â± s.e.m.</p>
            </fn>
            <fn id="t003fn002">
              <p><sup>$</sup> The weighted tau was calculated from the Amplitude of the fast and slow components (<italic>Amp</italic><sub><italic>FAST</italic></sub>, <italic>Amp</italic><sub><italic>SLOW</italic></sub>) by Ï<sub><bold>W</bold></sub> = <italic>Amp</italic><sub><italic>FAST</italic></sub>/(<italic>Amp</italic><sub><italic>FAST</italic></sub>+<italic>Amp</italic><sub><italic>SLOW</italic></sub>) <italic>Ã</italic> Ï<sub><bold>FAST</bold></sub>
<bold>+</bold>
<italic>Amp</italic><sub><italic>SLOW</italic></sub>/(<italic>Amp</italic><sub><italic>FAST</italic></sub>+<italic>Amp</italic><sub><italic>SLOW</italic></sub>) <italic>Ã</italic> Ï<sub><bold>SLOW</bold></sub></p>
            </fn>
            <fn id="t003fn003">
              <p>* p &lt; 0.01, compared with WT 2A, unpaired t-test</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="sec020">
        <title>GluN2A(D731N) mutation changes channel open probability</title>
        <p>To evaluate the effects of this mutant on channel open probability, the receptors were activated by EC<sub>50</sub> concentrations of glutamate (4 Î¼M for WT 2A, 13.7 mM for 2A-D731N, 6 Î¼M for 2A/2A, 6.5 mM for D731N/2A, and 30 mM for D731N/D731N, see <xref rid="pone.0170818.t002" ref-type="table">Table 2</xref>) with saturating concentration (100 Î¼M) of glycine. The rate of channel block by 200 nM MK801 was measured using TEVC recordings from <italic>Xenopus</italic> oocytes to estimate channel open probability [<xref rid="pone.0170818.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0170818.ref036" ref-type="bibr">36</xref>,<xref rid="pone.0170818.ref037" ref-type="bibr">37</xref>]. The di-heteromeric mutant (2A-D731N) receptors show a slower rate of inhibition, which we interpret as a decreased channel open probability. We estimate the reduction in open probability to be 6.0-fold (0.046 compared to 0.28 of WT 2A; <xref ref-type="fig" rid="pone.0170818.g006">Fig 6A and 6C</xref>; <xref rid="pone.0170818.t004" ref-type="table">Table 4</xref>; see <xref ref-type="sec" rid="sec006">Methods</xref>). In NMDARs that contain two copies of the mutation (D731N/D731N), there was a 6.1-fold reduction in open probability (0.064) compared to the 0.37 of WT 2A/2A. NMDARs with a single copy of the mutation (D731N/2A) showed 1.5-fold decrease in open probability (0.249) (<xref ref-type="fig" rid="pone.0170818.g006">Fig 6B and 6C</xref>; <xref rid="pone.0170818.t004" ref-type="table">Table 4</xref>).</p>
        <fig id="pone.0170818.g006" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0170818.g006</object-id>
          <label>Fig 6</label>
          <caption>
            <title>GluN2A(D731N) decreases channel open probability.</title>
            <p>(<bold>A-C</bold>) Representative TEVC recordings from WT and the mutant di-heteromeric and tri-heteromeric receptors from <italic>Xenopus</italic> oocytes show the time course of MK801 (0.2 Î¼M) inhibition. The receptors were activated by EC<sub>50</sub> concentrations of glutamate with saturating concentration (100 Î¼M) of glycine at holding potential of -40 mV. The di-heteromeric mutant (2A-D731N) and tri-heteromeric receptors with two-copies of the mutant subunit (D731N/D731N) showed a prolonged inhibition rate, reflecting a decreased channel open probability. A single copy mutant subunit (D731N/2A) also produced a mild but significant prolongation in MK801 inhibition rate. (<bold>D,E</bold>) The channel open probability was evaluated by measuring the degree of MTSEA (200 Î¼M) potentiation using TEVC recordings from <italic>Xenopus</italic> oocytes expressing the WT GluN2A (<italic>left panel</italic>) or the mutant GluN2A(D731N) (<italic>right panel</italic>) coexpressed with GluN1(A652C) at a holding potential of -40 mV in presence of EC<sub>50</sub> concentrations of glutamate with saturating concentration (100 Î¼M) of glycine (open bar) and 0.2 mM MTSEA (closed bar). Fitted parameters describing the exponential time course for MK801 inhibition and calculated open probability are given in <xref rid="pone.0170818.t004" ref-type="table">Table 4</xref>.</p>
          </caption>
          <graphic xlink:href="pone.0170818.g006"/>
        </fig>
        <table-wrap id="pone.0170818.t004" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0170818.t004</object-id>
          <label>Table 4</label>
          <caption>
            <title>Summary of channel open probability for GluN2A(D731N).</title>
          </caption>
          <alternatives>
            <graphic id="pone.0170818.t004g" xlink:href="pone.0170818.t004"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="center" rowspan="1" colspan="1">Â </th>
                  <th align="center" colspan="2" rowspan="1">di-heteromeric receptors</th>
                  <th align="center" colspan="3" rowspan="1">tri-heteromeric receptors</th>
                </tr>
                <tr>
                  <th align="center" rowspan="1" colspan="1">Â </th>
                  <th align="center" rowspan="1" colspan="1">WT 2A</th>
                  <th align="center" rowspan="1" colspan="1">2A-D731N</th>
                  <th align="center" rowspan="1" colspan="1">WT 2A/2A</th>
                  <th align="center" rowspan="1" colspan="1">D731N/2A</th>
                  <th align="center" rowspan="1" colspan="1">D731N/D731N</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold><italic>1/Tau</italic>-MK801, ms</bold>
                    <sup>
                      <bold>-1</bold>
                    </sup>
                  </td>
                  <td align="center" rowspan="1" colspan="1">0.334 Â± 0.026</td>
                  <td align="center" rowspan="1" colspan="1">0.056 Â± 0.002 <xref ref-type="table-fn" rid="t004fn003">*</xref></td>
                  <td align="center" rowspan="1" colspan="1">0.405 Â± 0.04</td>
                  <td align="center" rowspan="1" colspan="1">0.273 Â± 0.035 <xref ref-type="table-fn" rid="t004fn004"><sup>#</sup></xref></td>
                  <td align="center" rowspan="1" colspan="1">0.066 Â± 0.016 <xref ref-type="table-fn" rid="t004fn004"><sup>#</sup></xref>
<xref ref-type="table-fn" rid="t004fn005"><sup>%</sup></xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>POPEN (from MK801)</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">0.278 Â± 0.024</td>
                  <td align="center" rowspan="1" colspan="1">0.046 Â± 0.002 <xref ref-type="table-fn" rid="t004fn003">*</xref></td>
                  <td align="center" rowspan="1" colspan="1">0.370 Â± 0.039</td>
                  <td align="center" rowspan="1" colspan="1">0.249 Â± 0.032 <xref ref-type="table-fn" rid="t004fn004"><sup>#</sup></xref></td>
                  <td align="center" rowspan="1" colspan="1">0.064 Â± 0.014 <xref ref-type="table-fn" rid="t004fn004"><sup>#</sup></xref>
<xref ref-type="table-fn" rid="t004fn005"><sup>%</sup></xref></td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>n</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">8</td>
                  <td align="center" rowspan="1" colspan="1">10</td>
                  <td align="center" rowspan="1" colspan="1">8</td>
                  <td align="center" rowspan="1" colspan="1">8</td>
                  <td align="center" rowspan="1" colspan="1">17</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>MTSEA Potentiation (% of control)</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">312 Â± 17</td>
                  <td align="center" rowspan="1" colspan="1">1541 Â± 106 <xref ref-type="table-fn" rid="t004fn003">*</xref></td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>POPEN (from MTSEA)</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">0.222 Â± 0.015</td>
                  <td align="center" rowspan="1" colspan="1">0.047 Â± 0.003 <xref ref-type="table-fn" rid="t004fn003">*</xref></td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                </tr>
                <tr>
                  <td align="center" rowspan="1" colspan="1">
                    <bold>n</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">10</td>
                  <td align="center" rowspan="1" colspan="1">16</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                  <td align="center" rowspan="1" colspan="1">â</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="t004fn001">
              <p>Evaluated by TEVC recordings on <italic>Xenopus</italic> oocytes, see <xref ref-type="sec" rid="sec006">Materials and Methods</xref>.</p>
            </fn>
            <fn id="t004fn002">
              <p>The data were expressed as mean Â± s.e.m. (n) is the number of cells recorded from.</p>
            </fn>
            <fn id="t004fn003">
              <p>* p &lt; 0.01, compared with WT 2A, unpaired t-test</p>
            </fn>
            <fn id="t004fn004">
              <p><sup>#</sup> p &lt; 0.01 compared with WT 2A/2A</p>
            </fn>
            <fn id="t004fn005">
              <p><sup>%</sup> p &lt; 0.01 compared with D731N/2A, one way ANOVA, <italic>post hoc</italic> Tukey test</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>We further evaluated channel open probability by measuring the degree of MTSEA (200 Î¼M, closed bar in <xref ref-type="fig" rid="pone.0170818.g006">Fig 6D</xref>) potentiation using TEVC recordings from <italic>Xenopus</italic> oocytes expressing the WT GluN2A (<italic>left panel</italic>, <xref ref-type="fig" rid="pone.0170818.g006">Fig 6D</xref>) or the mutant GluN2(D731N) (<italic>right panel</italic>, <xref ref-type="fig" rid="pone.0170818.g006">Fig 6D</xref>) coexpressed with GluN1(A652C) at holding potential of -40 mV. Because the low potency of glutamate at mutant receptors prevented us from using saturating concentrations of glutamate, we assessed MTSEA potentiation on responses activated by EC<sub>50</sub> concentrations of glutamate (4.0 Î¼M glutamate for WT GluN2A and 13.7 mM glutamate for GluN2A(D731N) with 100 Î¼M glycine. Channel open probability is inversely correlated with the degree of potentiation [<xref rid="pone.0170818.ref030" ref-type="bibr">30</xref>], and thus we interpret the increase in the current response produced by MTSEA treatment of GluN1(A652C)/GluN2A(D731N) receptors to reflect a significant decrease in open probability by the D731N mutation (calculated P<sub>OPEN</sub> 0.05 for 2A-D731N <italic>vs</italic>. 0.22 for WT 2A; <xref ref-type="fig" rid="pone.0170818.g006">Fig 6E</xref>; <xref rid="pone.0170818.t004" ref-type="table">Table 4</xref>). These data are consistent with the change in the time course of the onset of MK801 inhibition, indicating the mutant D731N receptors decrease channel open probability.</p>
      </sec>
    </sec>
    <sec sec-type="conclusions" id="sec021">
      <title>Discussion</title>
      <p>Recent advances in whole exome sequencing have improved affordability of genotyping and aided in understanding undiagnosed diseases as well as epilepsy syndromes. This has led to compelling data that NMDAR mutations contribute to epilepsy with studies suggesting that <italic>GRIN2A</italic> mutations are associated with 9% of epilepsy-aphasia spectrum disorders and 20% of Landau-Kleffner Syndrome (LKS), continuous spikes and waves during slow-wave sleep (CSWS), and atypical rolandic epilepsy (aRE) cases [<xref rid="pone.0170818.ref013" ref-type="bibr">13</xref>â<xref rid="pone.0170818.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0170818.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0170818.ref038" ref-type="bibr">38</xref>]. Monogenic mutations have been shown to cause epilepsy, especially when mutations occur in genes encoding ion channels [<xref rid="pone.0170818.ref039" ref-type="bibr">39</xref>].</p>
      <p>We describe the functional effects of a <italic>GRIN2A</italic> missense mutation in the S2 region of the glutamate binding domain (LBD) of the GluN2A NMDA subunit found in three unrelated patients (<xref rid="pone.0170818.t001" ref-type="table">Table 1</xref>). This amino acid change at residue 731 from aspartic acid to asparagine (D731N) results in the substitution of an uncharged amino acid for a charged amino acid. According to the crystal structure of the GluN2A [<xref rid="pone.0170818.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0170818.ref041" ref-type="bibr">41</xref>], the residue Glu2A-D731 occupies a strategic position in close proximity to the glutamate molecule (<xref ref-type="fig" rid="pone.0170818.g001">Fig 1D</xref>). Functional analysis of GluN2A-D731N reveals a drastic decrease in glutamate potency (~3,000-fold). This likely reflects interactions (a water bridge) between the amino group of the agonist glutamate and the residue at position 731 [<xref rid="pone.0170818.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0170818.ref042" ref-type="bibr">42</xref>]. The homologous positions of GluN2A-D731 were also reported to be the critical glycine binding positions in GluN1 [<xref rid="pone.0170818.ref043" ref-type="bibr">43</xref>]. In the GluN1 subunit, mutation of the homologous position GluN1-D732 to glutamate (D732E), asparagine (D732N), alanine (D732A), or glycine (D732G) decreased the potency of glycine by over 4,000-fold [<xref rid="pone.0170818.ref043" ref-type="bibr">43</xref>]. No response or very small responses to 10 mM glutamate and plus 10â30 mM glycine were observed in receptors harboring GluN2A-D731A, GluN2A-D731E, GluN2B-D732A, or GluN2B-D732E [<xref rid="pone.0170818.ref042" ref-type="bibr">42</xref>â<xref rid="pone.0170818.ref044" ref-type="bibr">44</xref>]. Mutation of Asp at position 731 may destabilize the glutamate binding pocket, resulting in a strong decrease of glutamate potency. Decreased potency for glutamate in the mutant receptor will reduce activation both at the synapse as well as for extrasynaptic NMDA receptors compared to the WT receptors. The decreased potency is also expected to accelerate the deactivation of the current responses following glutamate removal, and thus accelerate the EPSC time course [<xref rid="pone.0170818.ref035" ref-type="bibr">35</xref>, <xref rid="pone.0170818.ref045" ref-type="bibr">45</xref>]. Interestingly, we also found that the mutant GluN2A-D731N also enhanced sensitivity to both zinc and protons, consistent with the strong coupling between downstream mechanisms that mediate proton and Zn<sup>2+</sup> inhibition [<xref rid="pone.0170818.ref046" ref-type="bibr">46</xref>,<xref rid="pone.0170818.ref047" ref-type="bibr">47</xref>]. The enhanced sensitivity to negative allosteric modulators may reflect the enhanced sensitivity of channel opening in NMDARs harboring the D731N mutation to inhibition given the reduced open probability. However, further study is required to explain how the mutation in the agonist binding domain affects the zinc and proton inhibition. The increase in zinc and proton inhibition further diminishes activity of the mutant receptor through enhanced inhibition at physiological concentrations of these negative modulators. The combination of these two effects will strongly reduce NMDAR activation compared to WT GluN2A-containing NMDA receptors. Thus, our data suggest that the aspartic acid at position 731 residues is critical to NMDAR function.</p>
      <p>Previously published reports suggest that epilepsy is associated with loss-of-function and gain-of-function GluN2A mutations [<xref rid="pone.0170818.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0170818.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0170818.ref020" ref-type="bibr">20</xref>â<xref rid="pone.0170818.ref022" ref-type="bibr">22</xref>,<xref rid="pone.0170818.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0170818.ref048" ref-type="bibr">48</xref>], indicating that either enhanced or reduced NMDAR function could lead to epilepsy. In the brain, the neuronal network is constituted by excitatory neurons (as glutamatergic neurons) and inhibitory neurons (as GABAergic neurons). GluN2A/<italic>GRIN2A</italic> is expressed in both glutamatergic and GABAergic neurons of in the human fetal cerebral cortex [<xref rid="pone.0170818.ref049" ref-type="bibr">49</xref>] and in GABAergic interneurons in the prefrontal cortex [<xref rid="pone.0170818.ref050" ref-type="bibr">50</xref>]. Therefore, the alternation of functions and expression levels of GluN2A (caused by GluN2A mutations) in different neuron types may have different impacts on the balance of excitation and inhibition in brain circuits, as well as circuit development. This study indicates that loss-of-function GluN2A mutants may impair the inhibitory effect of GABAergic neurons and contribute to epilepsy.</p>
      <p>The phenotype of all three unrelated patients was marked with developmental delay, particularly in language. All patients exhibited temporal lobe seizures. For at least one of the patients (in this study), EEG recordings confirmed seizure activity during sleep. Such encephalopathy with status epilepticus during sleep (ESES) has been shown to disrupt neural processes local to the site of activity [<xref rid="pone.0170818.ref051" ref-type="bibr">51</xref>]. Slow-wave activity during sleep is important in learning, with EEG activity correlated to similar areas in sleep and wakefulness [<xref rid="pone.0170818.ref052" ref-type="bibr">52</xref>]. All three probands experienced rolandic epilepsy from the temporal lobes, an area associated with language function. It is possible that the normal processes during sleep necessary for language development are perturbed by mutant NMDA receptor hypo-activity, disrupting normal circuitry. Further experimentation is required to validate this theory, but there is strong evidence for the importance in screening for NMDAR mutations in cases of idiopathic epilepsy. This study shows the functional effects of a <italic>GRIN2A</italic> mutation in a highly conserved portion of the ABD. Such work could ultimately lead to the identification of a new generation of drugs to mitigate or prevent the devastating effects of disorders such as LKS and other epilepsy-aphasia spectrum disorders.</p>
      <p>Correlating phenotype to genotype is difficult because many genes may be involved, along with environmental factors, in expression of seizures. Gene sequencing technology may help to solve this problem, and has allowed us to identify multiple patients with an identical <italic>GRIN2A</italic> mutation. Functional analysis of <italic>de novo</italic> mutations verified through genomic sequencing in trios will aid in the understanding of certain types of epilepsy, which will ultimately lead to better treatment. Moreover, understanding the functional effect of mutations is clinically important, and may lead to better therapeutic solutions to their corresponding diseases.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Jing Zhang for outstanding technical assistance, and Riley Perszyk, and Dr. Feng Yi for critical assistance with experiments and analysis. This work was supported by the Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development (NICHD) of the National Institutes of Health (NIH) under award number R01HD082373 to H.Y., by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) under award number R01NS036654, R01NS065371, R24NS092989 to S.F.T., by the Xiangya-Emory Medical Schools Visiting Student Program to W.C.; by the National Basic Research Program of China (973 program, grant number: 2012CB944600), by the National Natural Science Foundation of China (grant number: 81271439), by the Beijing Natural Science Foundation (grant number: 7151010), by the Beijing Municipal Science &amp; Technology Commission (grant number: Z161100000216133), by the Beijing Institute for Brain Disorders Foundation (grant number: BIBDPXM2014_014226_000016) and the Beijing Municipal Natural Science Key Project (grant number: 15G10050). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0170818.ref001">
        <label>1</label>
        <mixed-citation publication-type="journal"><name><surname>Traynelis</surname><given-names>SF</given-names></name>, <name><surname>Wollmuth</surname><given-names>LP</given-names></name>, <name><surname>McBain</surname><given-names>CJ</given-names></name>, <name><surname>Menniti</surname><given-names>FS</given-names></name>, <name><surname>Vance</surname><given-names>KM</given-names></name>, <name><surname>Ogden</surname><given-names>KK</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Glutamate receptor ion channels: structure, regulation, and function</article-title>. <source>Pharmacol Rev</source>
<volume>62</volume>: <fpage>405</fpage>â<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1124/pr.109.002451</pub-id>
<?supplied-pmid 20716669?><pub-id pub-id-type="pmid">20716669</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref002">
        <label>2</label>
        <mixed-citation publication-type="journal"><name><surname>Dingledine</surname><given-names>R</given-names></name>, <name><surname>Borges</surname><given-names>K</given-names></name>, <name><surname>Bowie</surname><given-names>D</given-names></name>, <name><surname>Traynelis</surname><given-names>SF</given-names></name> (<year>1999</year>) <article-title>The glutamate receptor ion channels</article-title>. <source>Pharmacol Rev</source>
<volume>51</volume>: <fpage>7</fpage>â<lpage>61</lpage>. <?supplied-pmid 10049997?><pub-id pub-id-type="pmid">10049997</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref003">
        <label>3</label>
        <mixed-citation publication-type="journal"><name><surname>Wollmuth</surname><given-names>LP</given-names></name>, <name><surname>Sobolevsky</surname><given-names>AI</given-names></name> (<year>2004</year>) <article-title>Structure and gating of the glutamate receptor ion channel</article-title>. <source>Trends Neurosci</source>
<volume>27</volume>: <fpage>321</fpage>â<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2004.04.005</pub-id>
<?supplied-pmid 15165736?><pub-id pub-id-type="pmid">15165736</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref004">
        <label>4</label>
        <mixed-citation publication-type="journal"><name><surname>Akazawa</surname><given-names>C</given-names></name>, <name><surname>Shigemoto</surname><given-names>R</given-names></name>, <name><surname>Bessho</surname><given-names>Y</given-names></name>, <name><surname>Nakanishi</surname><given-names>S</given-names></name>, <name><surname>Mizuno</surname><given-names>N</given-names></name> (<year>1994</year>) <article-title>Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats</article-title>. <source>J Comp Neurol</source>
<volume>347</volume>: <fpage>150</fpage>â<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1002/cne.903470112</pub-id>
<?supplied-pmid 7798379?><pub-id pub-id-type="pmid">7798379</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref005">
        <label>5</label>
        <mixed-citation publication-type="journal"><name><surname>Saft</surname><given-names>C</given-names></name>, <name><surname>Epplen</surname><given-names>JT</given-names></name>, <name><surname>Wieczorek</surname><given-names>S</given-names></name>, <name><surname>Landwehrmeyer</surname><given-names>GB</given-names></name>, <name><surname>Roos</surname><given-names>RA</given-names></name>, <name><surname>de Yebenes</surname><given-names>JG</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>NMDA receptor gene variations as modifiers in Huntington disease: a replication study</article-title>. <source>PLoS Curr</source>
<volume>3</volume>: <fpage>RRN1247</fpage>
<pub-id pub-id-type="doi">10.1371/currents.RRN1247</pub-id>
<?supplied-pmid 21989477?><pub-id pub-id-type="pmid">21989477</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref006">
        <label>6</label>
        <mixed-citation publication-type="journal"><name><surname>Arning</surname><given-names>L</given-names></name>, <name><surname>Kraus</surname><given-names>PH</given-names></name>, <name><surname>Valentin</surname><given-names>S</given-names></name>, <name><surname>Saft</surname><given-names>C</given-names></name>, <name><surname>Andrich</surname><given-names>J</given-names></name>, <name><surname>Epplen</surname><given-names>JT</given-names></name> (<year>2005</year>) <article-title>NR2A and NR2B receptor gene variations modify age at onset in Huntington disease</article-title>. <source>Neurogenetics</source>
<volume>6</volume>: <fpage>25</fpage>â<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1007/s10048-004-0198-8</pub-id>
<?supplied-pmid 15742215?><pub-id pub-id-type="pmid">15742215</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref007">
        <label>7</label>
        <mixed-citation publication-type="journal"><name><surname>Hallett</surname><given-names>PJ</given-names></name>, <name><surname>Standaert</surname><given-names>DG</given-names></name> (<year>2004</year>) <article-title>Rationale for and use of NMDA receptor antagonists in Parkinson's disease</article-title>. <source>Pharmacol Ther</source>
<volume>102</volume>: <fpage>155</fpage>â<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2004.04.001</pub-id>
<?supplied-pmid 15163596?><pub-id pub-id-type="pmid">15163596</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref008">
        <label>8</label>
        <mixed-citation publication-type="journal"><name><surname>Hamza</surname><given-names>TH</given-names></name>, <name><surname>Chen</surname><given-names>H</given-names></name>, <name><surname>Hill-Burns</surname><given-names>EM</given-names></name>, <name><surname>Rhodes</surname><given-names>SL</given-names></name>, <name><surname>Montimurro</surname><given-names>J</given-names></name>, <name><surname>Kay</surname><given-names>DM</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee</article-title>. <source>PLoS Genet</source>
<volume>7</volume>: <fpage>e1002237</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1002237</pub-id>
<?supplied-pmid 21876681?><pub-id pub-id-type="pmid">21876681</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref009">
        <label>9</label>
        <mixed-citation publication-type="journal"><name><surname>Coyle</surname><given-names>JT</given-names></name>, <name><surname>Tsai</surname><given-names>G</given-names></name>, <name><surname>Goff</surname><given-names>D</given-names></name> (<year>2003</year>) <article-title>Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia</article-title>. <source>Ann N Y Acad Sci</source>
<volume>1003</volume>: <fpage>318</fpage>â<lpage>327</lpage>. <?supplied-pmid 14684455?><pub-id pub-id-type="pmid">14684455</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref010">
        <label>10</label>
        <mixed-citation publication-type="journal"><name><surname>Saunders</surname><given-names>JA</given-names></name>, <name><surname>Tatard-Leitman</surname><given-names>VM</given-names></name>, <name><surname>Suh</surname><given-names>J</given-names></name>, <name><surname>Billingslea</surname><given-names>EN</given-names></name>, <name><surname>Roberts</surname><given-names>TP</given-names></name>, <name><surname>Siegel</surname><given-names>SJ</given-names></name> (<year>2013</year>) <article-title>Knockout of NMDA receptors in parvalbumin interneurons recreates autism-like phenotypes</article-title>. <source>Autism Res</source>
<volume>6</volume>: <fpage>69</fpage>â<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1264</pub-id>
<?supplied-pmid 23441094?><pub-id pub-id-type="pmid">23441094</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref011">
        <label>11</label>
        <mixed-citation publication-type="journal"><name><surname>Won</surname><given-names>H</given-names></name>, <name><surname>Lee</surname><given-names>HR</given-names></name>, <name><surname>Gee</surname><given-names>HY</given-names></name>, <name><surname>Mah</surname><given-names>W</given-names></name>, <name><surname>Kim</surname><given-names>JI</given-names></name>, <name><surname>Lee</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function</article-title>. <source>Nature</source>
<volume>486</volume>: <fpage>261</fpage>â<lpage>265</lpage>. <pub-id pub-id-type="doi">10.1038/nature11208</pub-id>
<?supplied-pmid 22699620?><pub-id pub-id-type="pmid">22699620</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref012">
        <label>12</label>
        <mixed-citation publication-type="journal"><name><surname>Zeron</surname><given-names>MM</given-names></name>, <name><surname>Hansson</surname><given-names>O</given-names></name>, <name><surname>Chen</surname><given-names>N</given-names></name>, <name><surname>Wellington</surname><given-names>CL</given-names></name>, <name><surname>Leavitt</surname><given-names>BR</given-names></name>, <name><surname>Brundin</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease</article-title>. <source>Neuron</source>
<volume>33</volume>: <fpage>849</fpage>â<lpage>860</lpage>. <?supplied-pmid 11906693?><pub-id pub-id-type="pmid">11906693</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref013">
        <label>13</label>
        <mixed-citation publication-type="journal"><name><surname>Carvill</surname><given-names>GL</given-names></name>, <name><surname>Regan</surname><given-names>BM</given-names></name>, <name><surname>Yendle</surname><given-names>SC</given-names></name>, <name><surname>O'Roak</surname><given-names>BJ</given-names></name>, <name><surname>Lozovaya</surname><given-names>N</given-names></name>, <name><surname>Bruneau</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>GRIN2A mutations cause epilepsy-aphasia spectrum disorders</article-title>. <source>Nat Genet</source>
<volume>45</volume>: <fpage>1073</fpage>â<lpage>1076</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2727</pub-id>
<?supplied-pmid 23933818?><pub-id pub-id-type="pmid">23933818</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref014">
        <label>14</label>
        <mixed-citation publication-type="journal"><name><surname>Lemke</surname><given-names>JR</given-names></name>, <name><surname>Hendrickx</surname><given-names>R</given-names></name>, <name><surname>Geider</surname><given-names>K</given-names></name>, <name><surname>Laube</surname><given-names>B</given-names></name>, <name><surname>Schwake</surname><given-names>M</given-names></name>, <name><surname>Harvey</surname><given-names>RJ</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy</article-title>. <source>Ann Neurol</source>
<volume>75</volume>: <fpage>147</fpage>â<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24073</pub-id>
<?supplied-pmid 24272827?><pub-id pub-id-type="pmid">24272827</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref015">
        <label>15</label>
        <mixed-citation publication-type="journal"><name><surname>Lesca</surname><given-names>G</given-names></name>, <name><surname>Rudolf</surname><given-names>G</given-names></name>, <name><surname>Bruneau</surname><given-names>N</given-names></name>, <name><surname>Lozovaya</surname><given-names>N</given-names></name>, <name><surname>Labalme</surname><given-names>A</given-names></name>, <name><surname>Boutry-Kryza</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction</article-title>. <source>Nat Genet</source>
<volume>45</volume>: <fpage>1061</fpage>â<lpage>1066</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2726</pub-id>
<?supplied-pmid 23933820?><pub-id pub-id-type="pmid">23933820</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref016">
        <label>16</label>
        <mixed-citation publication-type="journal"><name><surname>de Ligt</surname><given-names>J</given-names></name>, <name><surname>Willemsen</surname><given-names>MH</given-names></name>, <name><surname>van Bon</surname><given-names>BW</given-names></name>, <name><surname>Kleefstra</surname><given-names>T</given-names></name>, <name><surname>Yntema</surname><given-names>HG</given-names></name>, <name><surname>Kroes</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Diagnostic exome sequencing in persons with severe intellectual disability</article-title>. <source>N Engl J Med</source>
<volume>367</volume>: <fpage>1921</fpage>â<lpage>1929</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1206524</pub-id>
<?supplied-pmid 23033978?><pub-id pub-id-type="pmid">23033978</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref017">
        <label>17</label>
        <mixed-citation publication-type="journal"><name><surname>Hamdan</surname><given-names>FF</given-names></name>, <name><surname>Gauthier</surname><given-names>J</given-names></name>, <name><surname>Araki</surname><given-names>Y</given-names></name>, <name><surname>Lin</surname><given-names>DT</given-names></name>, <name><surname>Yoshizawa</surname><given-names>Y</given-names></name>, <name><surname>Higashi</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability</article-title>. <source>Am J Hum Genet</source>
<volume>88</volume>: <fpage>306</fpage>â<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.02.001</pub-id>
<?supplied-pmid 21376300?><pub-id pub-id-type="pmid">21376300</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref018">
        <label>18</label>
        <mixed-citation publication-type="journal"><name><surname>Venkateswaran</surname><given-names>S</given-names></name>, <name><surname>Myers</surname><given-names>KA</given-names></name>, <name><surname>Smith</surname><given-names>AC</given-names></name>, <name><surname>Beaulieu</surname><given-names>CL</given-names></name>, <name><surname>Schwartzentruber</surname><given-names>JA</given-names></name>, <collab>FORGE Canada Consortium</collab>, <etal>et al</etal> (<year>2014</year>) <article-title>Whole-exome sequencing in an individual with severe global developmental delay and intractable epilepsy identifies a novel, de novo GRIN2A mutation</article-title>. <source>Epilepsia</source>
<volume>55</volume>: <fpage>e75</fpage>â<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1111/epi.12663</pub-id>
<?supplied-pmid 24903190?><pub-id pub-id-type="pmid">24903190</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref019">
        <label>19</label>
        <mixed-citation publication-type="journal"><name><surname>Burnashev</surname><given-names>N</given-names></name>, <name><surname>Szepetowski</surname><given-names>P</given-names></name> (<year>2015</year>) <article-title>NMDA receptor subunit mutations in neurodevelopmental disorders</article-title>. <source>Curr Opin Pharmacol</source>
<volume>20</volume>: <fpage>73</fpage>â<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2014.11.008</pub-id>
<?supplied-pmid 25498981?><pub-id pub-id-type="pmid">25498981</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref020">
        <label>20</label>
        <mixed-citation publication-type="journal"><name><surname>Swanger</surname><given-names>SA</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Wells</surname><given-names>G</given-names></name>, <name><surname>Burger</surname><given-names>PB</given-names></name>, <name><surname>Tankovic</surname><given-names>A</given-names></name>, <name><surname>Bhattacharya</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains</article-title>. <source>Am J Hum Genet</source>
<volume>99</volume>: <fpage>1261</fpage>â<lpage>1280</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.10.002</pub-id>
<?supplied-pmid 27839871?><pub-id pub-id-type="pmid">27839871</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref021">
        <label>21</label>
        <mixed-citation publication-type="journal"><name><surname>Endele</surname><given-names>S</given-names></name>, <name><surname>Rosenberger</surname><given-names>G</given-names></name>, <name><surname>Geider</surname><given-names>K</given-names></name>, <name><surname>Popp</surname><given-names>B</given-names></name>, <name><surname>Tamer</surname><given-names>C</given-names></name>, <name><surname>Stefanova</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes</article-title>. <source>Nat Genet</source>
<volume>42</volume>: <fpage>1021</fpage>â<lpage>1026</lpage>. <pub-id pub-id-type="doi">10.1038/ng.677</pub-id>
<?supplied-pmid 20890276?><pub-id pub-id-type="pmid">20890276</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref022">
        <label>22</label>
        <mixed-citation publication-type="journal"><name><surname>Lemke</surname><given-names>JR</given-names></name>, <name><surname>Lal</surname><given-names>D</given-names></name>, <name><surname>Reinthaler</surname><given-names>EM</given-names></name>, <name><surname>Steiner</surname><given-names>I</given-names></name>, <name><surname>Nothnagel</surname><given-names>M</given-names></name>, <name><surname>Alber</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes</article-title>. <source>Nat Genet</source>
<volume>45</volume>: <fpage>1067</fpage>â<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2728</pub-id>
<?supplied-pmid 23933819?><pub-id pub-id-type="pmid">23933819</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref023">
        <label>23</label>
        <mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Low</surname><given-names>CM</given-names></name>, <name><surname>Moody</surname><given-names>OA</given-names></name>, <name><surname>Jenkins</surname><given-names>A</given-names></name>, <name><surname>Traynelis</surname><given-names>SF</given-names></name> (<year>2015</year>) <article-title>Ionotropic GABA and Glutamate Receptor Mutations and Human Neurologic Diseases</article-title>. <source>Mol Pharmacol</source>
<volume>88</volume>: <fpage>203</fpage>â<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1124/mol.115.097998</pub-id>
<?supplied-pmid 25904555?><pub-id pub-id-type="pmid">25904555</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref024">
        <label>24</label>
        <mixed-citation publication-type="journal"><name><surname>DeVries</surname><given-names>SP</given-names></name>, <name><surname>Patel</surname><given-names>AD</given-names></name> (<year>2013</year>) <article-title>Two patients with a GRIN2A mutation and childhood-onset epilepsy</article-title>. <source>Pediatr Neurol</source>
<volume>49</volume>: <fpage>482</fpage>â<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2013.08.023</pub-id>
<?supplied-pmid 24125812?><pub-id pub-id-type="pmid">24125812</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref025">
        <label>25</label>
        <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Kong</surname><given-names>W</given-names></name>, <name><surname>Gao</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Gao</surname><given-names>K</given-names></name>, <name><surname>Xie</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Gene Mutation Analysis in 253 Chinese Children with Unexplained Epilepsy and Intellectual/Developmental Disabilities</article-title>. <source>PLoS One</source>
<volume>10</volume>: <fpage>e0141782</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0141782</pub-id>
<?supplied-pmid 26544041?><pub-id pub-id-type="pmid">26544041</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref026">
        <label>26</label>
        <mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>KB</given-names></name>, <name><surname>Ogden</surname><given-names>KK</given-names></name>, <name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Traynelis</surname><given-names>SF</given-names></name> (<year>2014</year>) <article-title>Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors</article-title>. <source>Neuron</source>
<volume>81</volume>: <fpage>1084</fpage>â<lpage>1096</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2014.01.035</pub-id>
<?supplied-pmid 24607230?><pub-id pub-id-type="pmid">24607230</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref027">
        <label>27</label>
        <mixed-citation publication-type="journal"><name><surname>Traynelis</surname><given-names>SF</given-names></name>, <name><surname>Burgess</surname><given-names>MF</given-names></name>, <name><surname>Zheng</surname><given-names>F</given-names></name>, <name><surname>Lyuboslavsky</surname><given-names>P</given-names></name>, <name><surname>Powers</surname><given-names>JL</given-names></name> (<year>1998</year>) <article-title>Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit</article-title>. <source>J Neurosci</source>
<volume>18</volume>: <fpage>6163</fpage>â<lpage>6175</lpage>. <?supplied-pmid 9698310?><pub-id pub-id-type="pmid">9698310</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref028">
        <label>28</label>
        <mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>KB</given-names></name>, <name><surname>Tajima</surname><given-names>N</given-names></name>, <name><surname>Risgaard</surname><given-names>R</given-names></name>, <name><surname>Perszyk</surname><given-names>RE</given-names></name>, <name><surname>Jorgensen</surname><given-names>L</given-names></name>, <name><surname>Vance</surname><given-names>KM</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors</article-title>. <source>Mol Pharmacol</source>
<volume>84</volume>: <fpage>114</fpage>â<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1124/mol.113.085803</pub-id>
<?supplied-pmid 23625947?><pub-id pub-id-type="pmid">23625947</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref029">
        <label>29</label>
        <mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Hansen</surname><given-names>KB</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Pierson</surname><given-names>TM</given-names></name>, <name><surname>Markello</surname><given-names>TC</given-names></name>, <name><surname>Fajardo</surname><given-names>KV</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Functional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy</article-title>. <source>Nat Commun</source>
<volume>5</volume>: <fpage>3251</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms4251</pub-id>
<?supplied-pmid 24504326?><pub-id pub-id-type="pmid">24504326</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref030">
        <label>30</label>
        <mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Erreger</surname><given-names>K</given-names></name>, <name><surname>Dravid</surname><given-names>SM</given-names></name>, <name><surname>Traynelis</surname><given-names>SF</given-names></name> (<year>2005</year>) <article-title>Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3</article-title>. <source>J Biol Chem</source>
<volume>280</volume>: <fpage>29708</fpage>â<lpage>29716</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M414215200</pub-id>
<?supplied-pmid 15970596?><pub-id pub-id-type="pmid">15970596</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref031">
        <label>31</label>
        <mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Hansen</surname><given-names>KB</given-names></name>, <name><surname>Vance</surname><given-names>KM</given-names></name>, <name><surname>Ogden</surname><given-names>KK</given-names></name>, <name><surname>Traynelis</surname><given-names>SF</given-names></name> (<year>2009</year>) <article-title>Control of NMDA receptor function by the NR2 subunit amino-terminal domain</article-title>. <source>J Neurosci</source>
<volume>29</volume>: <fpage>12045</fpage>â<lpage>12058</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1365-09.2009</pub-id>
<?supplied-pmid 19793963?><pub-id pub-id-type="pmid">19793963</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref032">
        <label>32</label>
        <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>CH</given-names></name>, <name><surname>Lu</surname><given-names>W</given-names></name>, <name><surname>Michel</surname><given-names>JC</given-names></name>, <name><surname>Goehring</surname><given-names>A</given-names></name>, <name><surname>Du</surname><given-names>J</given-names></name>, <name><surname>Song</surname><given-names>X</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>NMDA receptor structures reveal subunit arrangement and pore architecture</article-title>. <source>Nature</source>
<volume>511</volume>: <fpage>191</fpage>â<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1038/nature13548</pub-id>
<?supplied-pmid 25008524?><pub-id pub-id-type="pmid">25008524</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref033">
        <label>33</label>
        <mixed-citation publication-type="journal"><name><surname>Karakas</surname><given-names>E</given-names></name>, <name><surname>Furukawa</surname><given-names>H</given-names></name> (<year>2014</year>) <article-title>Crystal structure of a heterotetrameric NMDA receptor ion channel</article-title>. <source>Science</source>
<volume>344</volume>: <fpage>992</fpage>â<lpage>997</lpage>. <pub-id pub-id-type="doi">10.1126/science.1251915</pub-id>
<?supplied-pmid 24876489?><pub-id pub-id-type="pmid">24876489</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref034">
        <label>34</label>
        <mixed-citation publication-type="journal"><name><surname>Dyment</surname><given-names>DA</given-names></name>, <name><surname>Tetreault</surname><given-names>M</given-names></name>, <name><surname>Beaulieu</surname><given-names>CL</given-names></name>, <name><surname>Hartley</surname><given-names>T</given-names></name>, <name><surname>Ferreira</surname><given-names>P</given-names></name>, <name><surname>Chardon</surname><given-names>JW</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective study</article-title>. <source>Clin Genet</source>
<volume>88</volume>: <fpage>34</fpage>â<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1111/cge.12464</pub-id>
<?supplied-pmid 25046240?><pub-id pub-id-type="pmid">25046240</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref035">
        <label>35</label>
        <mixed-citation publication-type="journal"><name><surname>Lester</surname><given-names>RA</given-names></name>, <name><surname>Clements</surname><given-names>JD</given-names></name>, <name><surname>Westbrook</surname><given-names>GL</given-names></name>, <name><surname>Jahr</surname><given-names>CE</given-names></name> (<year>1990</year>) <article-title>Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents</article-title>. <source>Nature</source>
<volume>346</volume>: <fpage>565</fpage>â<lpage>567</lpage>. <pub-id pub-id-type="doi">10.1038/346565a0</pub-id>
<?supplied-pmid 1974037?><pub-id pub-id-type="pmid">1974037</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref036">
        <label>36</label>
        <mixed-citation publication-type="journal"><name><surname>Blanpied</surname><given-names>TA</given-names></name>, <name><surname>Boeckman</surname><given-names>FA</given-names></name>, <name><surname>Aizenman</surname><given-names>E</given-names></name>, <name><surname>Johnson</surname><given-names>JW</given-names></name> (<year>1997</year>) <article-title>Trapping channel block of NMDA-activated responses by amantadine and memantine</article-title>. <source>J Neurophysiol</source>
<volume>77</volume>: <fpage>309</fpage>â<lpage>323</lpage>. <?supplied-pmid 9120573?><pub-id pub-id-type="pmid">9120573</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref037">
        <label>37</label>
        <mixed-citation publication-type="journal"><name><surname>Dravid</surname><given-names>SM</given-names></name>, <name><surname>Erreger</surname><given-names>K</given-names></name>, <name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Nicholson</surname><given-names>K</given-names></name>, <name><surname>Le</surname><given-names>P</given-names></name>, <name><surname>Lyuboslavsky</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block</article-title>. <source>J Physiol</source>
<volume>581</volume>: <fpage>107</fpage>â<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2006.124958</pub-id>
<?supplied-pmid 17303642?><pub-id pub-id-type="pmid">17303642</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref038">
        <label>38</label>
        <mixed-citation publication-type="journal"><name><surname>Ghasemi</surname><given-names>M</given-names></name>, <name><surname>Schachter</surname><given-names>SC</given-names></name> (<year>2011</year>) <article-title>The NMDA receptor complex as a therapeutic target in epilepsy: a review</article-title>. <source>Epilepsy Behav</source>
<volume>22</volume>: <fpage>617</fpage>â<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2011.07.024</pub-id>
<?supplied-pmid 22056342?><pub-id pub-id-type="pmid">22056342</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref039">
        <label>39</label>
        <mixed-citation publication-type="journal"><name><surname>Nicita</surname><given-names>F</given-names></name>, <name><surname>De Liso</surname><given-names>P</given-names></name>, <name><surname>Danti</surname><given-names>FR</given-names></name>, <name><surname>Papetti</surname><given-names>L</given-names></name>, <name><surname>Ursitti</surname><given-names>F</given-names></name>, <name><surname>Castronovo</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>The genetics of monogenic idiopathic epilepsies and epileptic encephalopathies</article-title>. <source>Seizure</source>
<volume>21</volume>: <fpage>3</fpage>â<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.seizure.2011.08.007</pub-id>
<?supplied-pmid 21917483?><pub-id pub-id-type="pmid">21917483</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref040">
        <label>40</label>
        <mixed-citation publication-type="journal"><name><surname>Furukawa</surname><given-names>H</given-names></name>, <name><surname>Singh</surname><given-names>SK</given-names></name>, <name><surname>Mancusso</surname><given-names>R</given-names></name>, <name><surname>Gouaux</surname><given-names>E</given-names></name> (<year>2005</year>) <article-title>Subunit arrangement and function in NMDA receptors</article-title>. <source>Nature</source>
<volume>438</volume>: <fpage>185</fpage>â<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1038/nature04089</pub-id>
<?supplied-pmid 16281028?><pub-id pub-id-type="pmid">16281028</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref041">
        <label>41</label>
        <mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>S</given-names></name>, <name><surname>Stein</surname><given-names>RA</given-names></name>, <name><surname>Yoshioka</surname><given-names>C</given-names></name>, <name><surname>Lee</surname><given-names>CH</given-names></name>, <name><surname>Goehring</surname><given-names>A</given-names></name>, <name><surname>Mchaourab</surname><given-names>HS</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Mechanism of NMDA Receptor Inhibition and Activation</article-title>. <source>Cell</source>
<volume>165</volume>: <fpage>704</fpage>â<lpage>714</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.03.028</pub-id>
<?supplied-pmid 27062927?><pub-id pub-id-type="pmid">27062927</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref042">
        <label>42</label>
        <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>PE</given-names></name>, <name><surname>Geballe</surname><given-names>MT</given-names></name>, <name><surname>Stansfeld</surname><given-names>PJ</given-names></name>, <name><surname>Johnston</surname><given-names>AR</given-names></name>, <name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Jacob</surname><given-names>AL</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling</article-title>. <source>Mol Pharmacol</source>
<volume>67</volume>: <fpage>1470</fpage>â<lpage>1484</lpage>. <pub-id pub-id-type="doi">10.1124/mol.104.008185</pub-id>
<?supplied-pmid 15703381?><pub-id pub-id-type="pmid">15703381</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref043">
        <label>43</label>
        <mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>K</given-names></name>, <name><surname>Chao</surname><given-names>J</given-names></name>, <name><surname>Kashiwagi</surname><given-names>K</given-names></name>, <name><surname>Masuko</surname><given-names>T</given-names></name>, <name><surname>Igarashi</surname><given-names>K</given-names></name> (<year>1996</year>) <article-title>Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit</article-title>. <source>Mol Pharmacol</source>
<volume>50</volume>: <fpage>701</fpage>â<lpage>708</lpage>. <?supplied-pmid 8863813?><pub-id pub-id-type="pmid">8863813</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref044">
        <label>44</label>
        <mixed-citation publication-type="journal"><name><surname>Laube</surname><given-names>B</given-names></name>, <name><surname>Schemm</surname><given-names>R</given-names></name>, <name><surname>Betz</surname><given-names>H</given-names></name> (<year>2004</year>) <article-title>Molecular determinants of ligand discrimination in the glutamate-binding pocket of the NMDA receptor</article-title>. <source>Neuropharmacology</source>
<volume>47</volume>: <fpage>994</fpage>â<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.07.041</pub-id>
<?supplied-pmid 15555634?><pub-id pub-id-type="pmid">15555634</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref045">
        <label>45</label>
        <mixed-citation publication-type="journal"><name><surname>Vance</surname><given-names>KM</given-names></name>, <name><surname>Simorowski</surname><given-names>N</given-names></name>, <name><surname>Traynelis</surname><given-names>SF</given-names></name>, <name><surname>Furukawa</surname><given-names>H</given-names></name> (<year>2011</year>) <article-title>Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors</article-title>. <source>Nat Commun</source>
<volume>2</volume>: <fpage>294</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms1295</pub-id>
<?supplied-pmid 21522138?><pub-id pub-id-type="pmid">21522138</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref046">
        <label>46</label>
        <mixed-citation publication-type="journal"><name><surname>Low</surname><given-names>CM</given-names></name>, <name><surname>Zheng</surname><given-names>F</given-names></name>, <name><surname>Lyuboslavsky</surname><given-names>P</given-names></name>, <name><surname>Traynelis</surname><given-names>SF</given-names></name> (<year>2000</year>) <article-title>Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>97</volume>: <fpage>11062</fpage>â<lpage>11067</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.180307497</pub-id>
<?supplied-pmid 10984504?><pub-id pub-id-type="pmid">10984504</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref047">
        <label>47</label>
        <mixed-citation publication-type="journal"><name><surname>Erreger</surname><given-names>K</given-names></name>, <name><surname>Traynelis</surname><given-names>SF</given-names></name> (<year>2008</year>) <article-title>Zinc inhibition of rat NR1/NR2A N-methyl-D-aspartate receptors</article-title>. <source>J Physiol</source>
<volume>586</volume>: <fpage>763</fpage>â<lpage>778</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2007.143941</pub-id>
<?supplied-pmid 18048453?><pub-id pub-id-type="pmid">18048453</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref048">
        <label>48</label>
        <mixed-citation publication-type="journal"><name><surname>Ogden</surname><given-names>KK</given-names></name>, <name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Swanger</surname><given-names>SA</given-names></name>, <name><surname>McDaniel</surname><given-names>MJ</given-names></name>, <name><surname>Fan</surname><given-names>LZ</given-names></name>, <name><surname>Hu</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology</article-title>. <source>PLOS Genetics in press</source></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref049">
        <label>49</label>
        <mixed-citation publication-type="journal"><name><surname>Bagasrawala</surname><given-names>I</given-names></name>, <name><surname>Memi</surname><given-names>F</given-names></name>, <name><surname>N</surname><given-names>VR</given-names></name>, <name><surname>Zecevic</surname><given-names>N</given-names></name> (<year>2016</year>) <article-title>N-Methyl d-Aspartate Receptor Expression Patterns in the Human Fetal Cerebral Cortex</article-title>. <source>Cereb Cortex</source>.</mixed-citation>
      </ref>
      <ref id="pone.0170818.ref050">
        <label>50</label>
        <mixed-citation publication-type="journal"><name><surname>Xi</surname><given-names>D</given-names></name>, <name><surname>Keeler</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Houle</surname><given-names>JD</given-names></name>, <name><surname>Gao</surname><given-names>WJ</given-names></name> (<year>2009</year>) <article-title>NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: application of laser microdissection technique</article-title>. <source>J Neurosci Methods</source>
<volume>176</volume>: <fpage>172</fpage>â<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2008.09.013</pub-id>
<?supplied-pmid 18845188?><pub-id pub-id-type="pmid">18845188</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0170818.ref051">
        <label>51</label>
        <mixed-citation publication-type="journal"><name><surname>Tassinari</surname><given-names>CA</given-names></name>, <name><surname>Cantalupo</surname><given-names>G</given-names></name>, <name><surname>Rios-Pohl</surname><given-names>L</given-names></name>, <name><surname>Giustina</surname><given-names>ED</given-names></name>, <name><surname>Rubboli</surname><given-names>G</given-names></name> (<year>2009</year>) <article-title>Encephalopathy with status epilepticus during slow sleep: "the Penelope syndrome"</article-title>. <source>Epilepsia</source>
<volume>50</volume>
<issue>Suppl 7</issue>: <fpage>4</fpage>â<lpage>8</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0170818.ref052">
        <label>52</label>
        <mixed-citation publication-type="journal"><name><surname>Huber</surname><given-names>R</given-names></name>, <name><surname>Ghilardi</surname><given-names>MF</given-names></name>, <name><surname>Massimini</surname><given-names>M</given-names></name>, <name><surname>Tononi</surname><given-names>G</given-names></name> (<year>2004</year>) <article-title>Local sleep and learning</article-title>. <source>Nature</source>
<volume>430</volume>: <fpage>78</fpage>â<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1038/nature02663</pub-id>
<?supplied-pmid 15184907?><pub-id pub-id-type="pmid">15184907</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>